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Keloid scars are a result of such an aberration in wound healing, and are characterized by 
overabundant collagen/ECM deposition. Several treatment modalities have been explored 
but none of the treatments are effective. In spite of the large number of growth factors, 
cytokines and chemokines, that have been studied and are now known to play a role in its 
pathogenesis, the precise pathobiology leading to this scar formation remains largely 
unknown. Thus to identify new targets for therapeutic intervention, it is imperative to 
identify key modulators which are aberrantly expressed in keloids and to understand and 
assess the role of these modulators towards this fibrotic phenotype.  
  
This study aims to identify key modulators of cellular dynamics in keloid scars and 
investigate the effect of epithelial-mesenchymal interactions on the expression profile of 
these modulators using various in vitro models. This study further explores different 
growth factors or chemical drugs as potential therapeutic agents for keloid scars.  
 
Bearing in mind the importance of wound contraction and scar contracture in the wound 
healing process and scar formation respectively, an in vitro coculture model and a 
fibroblast-populated collagen lattice was employed to study the role of epithelial-
mesenchymal interaction towards a contractile phenotype.  It was observed that 
epithelial-mesenchymal interactions increased the contractile response of both normal 
and Keloid fibroblasts in vitro. In addition KF’s were shown to have an elevated 
contracile response to signals from the extracellular envirionment than normal 
fibroblasts, due to the increased expression of α-SMA, a contractile protein.  
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Further studies were performed to investigate the molecular effectors of keloid scars and 
the effect of epithelial-mesenchymal interaction on the expression profile of these 
effectors. 
 
Activin-A, a dimeric protein and a member of the TGF-β superfamily, has been shown to 
regulate various aspects of cell growth and differentiation in the repair of the skin 
mesenchyme and the epidermis. Thus the study aimed at investigating the role of activin 
and its antagonist, follistatin, in keloid pathogenesis. The findings strongly suggest that 
activin-A is a potent inducer of fibroblast activation and involved in the pathogenesis of 
keloids. They also emphasize the importance of follistatin in regulating activin-A 
bioactivity and suggest a possible therapeutic potential of follistatin in the treatment and 
prevention of keloids. 
 
Most of the growth factors and cytokines involved in the wound healing process seem to 
be immobilized at the cell surface and extracellular matrix via binding with 
proteoglycans, making them important modulators of cell dynamics. Thus the expression 
of two proteoglycans, namely syndecan-2 and decorin, were investigated in order to 
elucidate their roles in keloid pathogenesis. 
 
It was demonstrated that syndecan-2 and FGF-2 were not only overexpressed in keloid 
tissues but could also interact with each other resulting in the shedding of syndecan-2 
which could in turn activate a whole cascade of events resulting in keloidogenesis. In 
addition, decorin appeared to be downregulated in keloid tissues, and this protein with 




Finally the ubiquity of SCF and its tyrosine kinase receptor c-KIT in different kinds of 
cells and tissues, and their importance in wound healing and cancer led to their 
investigation as potential players in keloid pathogenesis. The study demonstrated that 
both SCF and c-KIT were upregulated in keloid scar tissues in vivo. They were also 
upregulated in cultured fibroblasts on stimulation with serum highlighting their possible 
role in the initial phases of the healing process when the wound is flooded with serum. In 
addition, we demonstrated that epithelial-mesenchymal interactions, mimicked by 
coculture of keratinocytes and fibroblasts in vitro, not only stimulated secretion of 
soluble form of SCF in keloid cocultures but also brought about shedding of the 
extracellular domain of c-KIT perhaps by upregulation of TACE which was also shown 
to be elevated in keloid tissues and keloid cocultures. Although the increased 
phosphorylation of c-KIT suggests the activation of SCF/c-KIT pathway in keloid 
cocultures, the exact role of the shed c-KIT is yet to be understood.  
 
Having identified a tyrosine kinase receptor system as a major player in keloid 
pathogenesis, we investigated the role of an established tyrosine kinase inhibitor, gleevec, 
as a possible therapeutic agent for keloid scars. It was observed that although gleevec did 
not have a significant effect on the proliferative potential of KF and KK, it was as able to 
downregulate the expression of ECM components as well as profibrotic factors in KF via 
inhibition of the c-KIT mediated PI3 kinase signaling pathway. It was also able to render 
the KF less bioenergetic by reducing the intracellular ATP levels and their rate of ATP 









































1.1 OVERVIEW OF THE WOUND HEALING PROCESS 
 
 
The wound healing process is a highly orchestrated process comprising of overlapping 
phases of inflammation, granulation tissue formation, angiogenesis and remodeling of the 
wound matrix (Clark et al., 1996). After wounding, the healing cascade immediately 
ensues with the release of various growth factors and cytokines from the serum of the 
disrupted blood vessels and degranulating platelets. The disruption of the blood vessels 
results in the formation of a fibrin clot which not only works as a barrier for invading 
microorganisms but also as a mesh for the binding of inflammatory cells, fibroblasts and 
growth factors (Tuan et al., 1998). Within a few hours of injury, inflammatory cells like 
neutrophils followed by monocytes and lymphocytes infiltrate the tissue and phagocytose 
the bacteria. In addition to their role in defence against microorganisms, inflammatory 
cells also serve as a pool for several growth factors and other macromolecules which are 
required to intiate the proliferative phase of the healing process. The proliferative phase 
involves the migration and proliferation of the keratinocytes from the wound edge 
followed by the proliferation of fibroblasts in the area neighbouring the wound. These 
fibroblasts then migrate into the wound area over a provisional wound matrix, deposit 
large amounts of ECM and subsequently transform into myofibroblasts with a contractile 
phenotype (Werner et al., 2003). Myofibroblasts are a group of actin rich fibroblasts and 
are known to play an important role in wound contraction. Proto-myofibroblasts 
differentiate to myofibroblasts by the production of α-SMA in order to generate more 
force for contracture (Tomasek et al., 2002; Roy et al., 2001). At the same time, 
angiogenic factors are released which promote angiogenesis by stimulating endothelial 
cell proliferation leading to capillary tube formation. The resulting wound connective 
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tissue is called granulation tissue with nerve sprouting occuring at the wound edge. 
Finally, a transition from granulation tissue to mature scar occurs, characterized by 
continued collagen synthesis and collagen catabolism. This process requires a balance 
between matrix biosynthesis and matrix degradation. A disruption in this balance either 
due to excessive matrix deposition or decreased matrix degradation leads to keloid and 
hypertrophic scars (Nedelec et al., 1996; Raghow et al., 1994).   
 
Figure 1: Schematic representation of different stages of wound repair (Adapted from 
Werner et al., 2003).  
A: 12–24 h after injury the wounded area is filled with a blood clot. Neutrophils invade into the 
clot. B: at days 3–7 after injury, neutrophils undergo apoptosis. Instead, macrophages are 
abundant in the wound tissue at this stage of repair. Endothelial cells migrate into the clot; they 
proliferate and form new blood vessels. Fibroblasts migrate into the wound tissue, where they 
proliferate and deposit extracellular matrix to form a granulation tissue. Keratinocytes proliferate 
at the wound edge and migrate down the injured dermis and above the provisional matrix. C: 1–2 
wk after injury the wound is completely filled with granulation tissue. Fibroblasts have 
transformed into myofibroblasts, leading to wound contraction and collagen deposition. The 
wound is completely covered with a neoepidermis. 
 
                          
                12–24 h    
                 
                Day 3-7    
                 
                1-2 Week    
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1.2  KELOID SCAR 
 
1.2.1 Clinical Characteristics of Keloid 
 
Keloid scars represent a pathological response to cutaneous injury and occur only in 
humans. The term ‘keloid’ is derived from a Greek word “khele” meaning crab claw 
(Ladin et al., 1995). Keloids usually appear as firm broad nodules, often erythematous 
and with a shiny surface (Marneros et al., 2004). A keloid scar extends beyond the 
confines of the original wound, does not regress spontaneously, grows in pseudotumor 
fashion with distortion of the lesion and tends to recur after excision. They are 
notoriously resistant to therapy. Numerous treatment modalities are available, none of 
which are consistently effective (Poochareon et al., 2003).  
Fibroproliferative disorders (FPD) involve various pathologic fibrotic conditions which 
constitute a leading cause of mortality in the United States (from a 5 year running 
average of the US bureau of vital statistics analysis of cause of death, 45% of deaths in 
1988 included death due to any form of fibrosis of any organ or tissue) (Kozak et al., 
1988; Bitterman et al., 1991). 
 
The keloid is a dermal form of FPD and although it has much less morbidity as compared 
to FPD of other organs, it causes considerable functional and aesthetic problems 
particularly after thermal injury (Tredget et al., 1990; Engrav et al., 1987). They have a 
propensity to occur in melanocyte-rich regions like face, neck, deltoid, presternal area 
and ear lobes (Kim et al., 2000; Crockett et al., 1964; Bayat et al., 2004). They have also 
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been reported to appear on the cornea (Shukla et al., 1975; Shoukrey et al., 1993; Lahav 
et al., 1982). 
 
Keloids are often compared with hypertrophic scars. Though their gross appearance is 
similar, hypertrophic scars unlike keloid scars, remain confined to the borders of the 
original wound and most of the times retain their shape (Mutalik et al., 2005) [21].  In 
addition, though hypertrophic scars develop within a few weeks after skin injury, keloid 
scars often show a delayed onset. 
 








There is believed to be a genetic and racial predisposition for the development of keloids 
in darker-skinned races compared to lighter skinned people. Some 15-20% of blacks, 
hispanics, and asians are afflicted with the disorder. Studies have reported incidence 
ratios between the two groups to range from 2:1 to 19:1 (Oluwasnami et al., 1974; Omo-
Dare et al., 1975). Both autosomal dominant and autosomal recessive genetic inheritance 
have been proposed but not confirmed (Omo-Dare et al., 1975). Although keloids are 
known to occur sporadically, some data suggest familial occurrence (Bloom et al., 1956). 
Differences in occurrence of keloids based on age and gender has also been reported. It 
has been shown to be predominant in females and in populations between the ages of 10 
and 30 (Cosman et al., 1961; Murray et al., 1981). Until now,  no susceptibility genes for 
keloid formation have been identified. TGF-β1, β2, β3, and TGF-β receptor 
polymorphisms have bene studies but has not yielded any statistically significant 
associations with keloids in case control studies (Bayat et al., 2002, 2003, 2004,2005 ). 
The Difficulty in identifying genes specific to keloids among patients with keloids may 
reflect genetic heterogeneity, whereby different genes contribute to keloid formation in 




Contrary to the appearance of organized fibres in normal skin, keloids have stretched 
collagen fibres aligned in the epidermal plane (Kelly et al., 1988). Excessive deposition 
of collagen and other extracellular matrix components along with increased blood vessels 
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and cells are observed in the histological sections of keloids. However the microvessels 
in keloids seem to be occluded perhaps to the increase proliferation of endothelial cells 
(Kischer et al., 1992). Keloid scars are also characterized by presence of tongue-like 
advancing edge underneath normal-appearing epidermis and papillary dermis (Lee et al., 
2004). Keloid sections are also characterized by a thickened epidermis and prominent 
disarray of fibrous fascicles/nodules. Mast cells, macrophages, epidermal langerhan cells 
have all been demonstrated to be elevated in keloids. However their role in keloid 
pathogenesis is not well understood. At higher magnification using scanning electron 
microscopy, the random nature of fiber orientation, varying fiber length and poor bundle 
formation in keloids are observed. 
 
Figure 3: H&E staining of normal skin and keloid scar tissues 
 
                    Normal Skin                                                           Keloid Scar 






1.2.4 Molecular Pathogenesis 
 
The wound healing process involves a complex interplay of cells, mediators, growth 
factors, and cytokines, leading to inflammation, cell proliferation, ECM deposition, 
contraction and remodeling. Thus a disruption in the cellular harmony leads to either a 
delayed healing response or execessive healing. The over healing response is marked by 
an over exuberant deposition of collagen and other extracellular matrix components like 
fibronectin by fibroblasts resulting in a scar which can either be keloidic or hypertophic. 
Previous studies have demonstrated that keloid-derived fibroblasts produced 20 times 
more type1 collagen than normal fibroblasts in vitro (Ladin et al., 1995; Ala-kokko et al., 
1987; Di cesare et al., 1990). 
 
Keloids are characterized by an increased proliferation of fibroblasts in vitro (Calderon et 
al., 1996). Recent studies have highlighted the importance of regulation of apoptosis, in 
scar establishment and the development of a pathological scar. Apoptosis-related genes 
and proteins have been shown to be down-regulated or mutated in keloid tissues and 
fibroblasts (Sayah et al., 1999; Chodon et al., 2000).  
 
The bioactivity of fibroblasts in fibrogenesis or excessive scar formation is regulated by a 
number of growth factors, of which the TGF-β family is thought to play a central role by 
its regulation of fibroblast proliferation, differentiation and matrix production. It is 
believed to enhance the production of ECM elements, such as fibronectin and collagen, 
and to upregulate the cellular expression of matrix receptor integrin (Tuan et al., 1998; 
Niessen et al., 1999; Kim et al., 2000). 
 
 12
TGF-β1 in particular has been widely implicated as a key modulator of cellular dynamics 
in fibrosis. Many groups have demonstrated increased levels of TGF–β in keloid tissues 
and other fibrotic disorders (Lee et al., 1999; Younai et al., 1994; Polo et al., 1999).  
Peltonen and co workers (1991) demonstrated that TGF-β1 mRNA and TGF-β1 protein 
were associated with excessive collagen synthesis and ECM accumulation in keloids. 
Shah’s group (1994) showed that blocking of TGF–β1 and TGF–β2 by the application of 
antibodies to cutaneous wounds markedly reduced scarring. Liu and team (2002) 
demonstrated, by an in vitro experiment, that the effects of TGF-β1 might be modulated 
by an autocrine loop and that this autocrine regulation might play an essential role in 
keloid formation and development.  Further, Chodon’s group (2000) reported that 
dysregulation in the Fas-mediated apoptosis, which occurred in normal wound healing, 
may be a factor contributing to scar formation and suggested a role for TGF-β1 in this 
resistance. 
 
Various other molecular pathways have been invoked in keloid pathogenesis. Platelet-
derived growth factor (PDGF) α-receptor expression was demonstrated to be elevated in 
KF and this corresponded to an increase in mitotic response of the fibroblasts on 
exposure to the PDGF isoforms (Haisa et al., 1994). An over expression of insulin-like 
growth factor-I (IGF-1) receptor in KF was also demonstrated to enhance their invasive 
potential highlighting the role of IGF-1 in keloid pathogenesis (Yoshimoto et al., 1999). 
An elevated expression of interleukin (IL)-6 (Xue et al., 2000) and VEGF (Wu et al., 
2004; Le et al., 2004) has also been reported in KF.  
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As the wound milieu consists of various cell types, it would be foolhardy to implicate 
fibroblasts alone as main players in fibrosis. Other cell types have also been shown to 
play a role in keloid pathogenesis directly or indirectly by influencing the fibroblasts. An 
elevated presence of mast cells was observed in keloids suggesting their possible role in 
keloid pathogenesis (Russel et al., 1977). Upon further investigation it was observed that 
an elevation of mast cell histamine resulted in an up-regulation of procollagen type 1 
production in KF (Kikuchi et al., 1995; Tredget et al., 1998). Another cell type which has 
been shown to play an important role in pathogenesis of scars is endothelial cells. Along 
with fibroblasts they are known to be important in production of collagen (Milsom et al., 
1973; Sollberg et al., 1991; Diegelmann et al., 1977). It has been observed that 
overproliferation of endothelial cells leads to occlusion of microvessel lumens in keloids 
resulting in a severe hypoxic condition (Kischer et al., 1982). The resulting hypoxia 
further stimulates endothelial cell proliferation and collagen production by fibroblasts by 
releasing growth factors like HIF-1α and VEGF (Knighton et al., 1983; Kischer et al., 
1992; Zhang et al., 2006).    
 
It is now becoming clear, that epithelial-mesenchymal interactions, initially applied to 
normal skin homeostasis (Maas-Szabowski et al., 2000; Mackenzie et al., 1994; Fusenig 
et al., 1994), are also instrumental in modulating fibroblast behaviour in keloids by 
paracrine influences. Previous laboratory-based findings showed that keloid-derived 
keratinocytes enhanced both normal and keloid-derived fibroblast proliferation and 
collagen synthesis in a co-culture system (Lim et al., 2001; Funayama et al., 2003; Xia et 
al., 2004). NF and KF cocultured with KK in defined serum-free media showed a higher 
rate of proliferation compared to that of coculture with NK (Lim et al., 2001; Funayama 
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et al., 2003; Xia et al., 2004). It was subsequently observed that KF co-cultured with KK 
produced increased amounts of both collagens I and collagen III compared with coculture 
with NK (Xia et al., 2004; Lim et al., 2002; Lim et al., 2003). Mitogen activation protein 
kinase (MAPK) and phosphatidyl-inositol-3 kinase (PI-3K) pathway activation have been 
observed in excessively proliferating KF cocultured with KK. When these fibroblasts 
were treated with MAPK-p44/42 specific inhibitor and PI-3K specific inhibitor, it caused 
complete nullification of collagen I and III  production, and significantly decreased 
fibronectin and laminin β2, all of which is produced in excess in keloidogenesis (Lim et 
al., 2003). Electron microscopic analysis also demonstrated that the appearance of 
collagen–extracellular matrix (ECM) produced by NF cocultured with KK in vitro, 
approximated the morphological appearance of in vivo keloid scar tissue (Lim et al., 
2002). Epithelial-mesenchymal interactions have been demonstrated to influence the 
expression of various transcription factors, growth factors and cytokines in vitro. Phan 
and his group (2005) demonstrated that epidermal-dermal interactions in keloids resulted 
in activation of the TGFβ-Smad axis which in turn played a crucial profibrotic role in 
keloid pathogenesis. Lim and his co-workers (2006) further demonstrated the modulation 
of yet another transcription factor STAT-3 by epithelial-mesenhcymal interactions in 
keloidic cells. Ong’s team (2007) used a two chambered coculture system to mimic 
epithelial-mesenchymal interaction and reported the expression and secretion of VEGF to 
be upregulated in KF on being coculutred with KK. Biologically active CTGF was also 




In addition to the increase of profibrotic molecules, anti fibrotic growth factors and 
enzymes have also been demonstrated to be downregulated in keloids. The balance 
between matrix metalloproteinase (MMP) and their inhibitors TIMP is critical for over all 
ECM turnover. Concentrations of collagenase inhibitors, α-globulins and plasminogen 
activator inhibitor -1 have been shown to be elevated in both in vitro and in vivo keloid 
samples, whereas the levels of degradative enzymes are frequently decreased 
(Diegelmann et al., 1977; Tuan et al., 1996). It has also been observed that MMP activity 
differs between KF and NF and these differences affect the phenotype (Uchida et al., 
2003).  
 
Although attempts are being made in understanding the molecular basis of keloid 
pathogenesis, the complexity of the repair process and the lack of proper in vitro and in 
vivo animal models have hindered progress in revealing the mechanisms underlying 
keloid scar formation. Thus it is imperative that new in vitro and in vivo methods are 
developed to assists researchers to delineate the dynamics of growth factors, deemed 
















Figure 4: Schematic representation of pathways potentially resulting in accumulation of 
collagen in fibrotic skin diseases (Adapted from Uitto et al., 2007).  
The net deposition of collagen is a balance between the rate of synthesis and the rate of 
degradation, both of which can be modulated by a number of factors, such as cytokines. These 
factors can be evoked by stimuli such as trauma to the skin. When superimposed on the 
individual’s genetic background, an imbalance in the flux through these pathways can result in 




1.2.5  Current Treatment 
 
Several modalities have been explored for either the treatment of keloid scars or 
prevention of their recurrence after surgery. However the several treatment strategies 
used, remain unsatisfactory. The current treatments available are as follows: 
 
Surgery: Surgical excision of hypertrophic and keloid scars when combined with steroid 
injection reduces the recurrence rate. However, excision alone in keloids is met with high 
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recurrence rate of 45 to 100% (Berman et al., 1995; 1996). Due to this, various adjunct 
therapies have been explored to reduce the problem of recurrence. 
 
Silicone Gel Sheeting: Silicone gel is a crosslinked polymer of dimethylsoloxane and is 
not only an effective adjunct to excision of keloids but also a prophylaxis to abnormal 
scarring in some incisions (Al-Attar et al., 2006). Despite the wide appreciation about the 
effect of silicone gel sheeting among the physicians, the mode of action of silicone is still 
unknown. Although silicone gel is comfortable, it requires active patient compliance and 
long-term application which is challenging on mobile and angled anatomical sites (Sproat 
et al., 1992). 
 
Corticosteroid Injection: Injection of triamcinolone is efficacious for the treatment of 
keloid scars in which it is used as a first-line therapy (Shons et al., 1983; Tang et al., 
1992). Corticosteroids are usually combined with surgical excision of the scar (Berman et 
al., 1996). However intralesional injections of corticosteroids are highly painful. In 
addition other side effects are skin atrophy, loss of pigmentation, and telangiectasia 
(Sproat et al., 1992).  
Pressure Therapy: Pressure therapy is an effective therapy with minimal side effects for 
keloids but its practical use is limited to ear lobes. It is generally used as a post operative 
adjunct for earlobe keloids (Brent et al., 1978; Russell et al., 2001). 
 
Radiotherapy: Radiotherapy has been used as monotherapy, and in combination with 
surgery, for hypertrophic scars and keloids. It is effective in reducing the recurrence rate 
of scars. However, monotherapy remains controversial because of anecdotal reports of 
carcinogenicity following the procedure (Thomas et al., 2002; Norris et al., 1995).  
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Cryotherapy: Cryotherapy is an option considered in treatment of very small scars like 
those arising from very severe acne (Layton et al., 1994). It uses rapid, repeated cooling 
and rewarming of tissue causing cell death and tissue sloughing (Al-Attar et al., 2006). 
Side-effects produced are slow healing of the wound along with tissue necrosis, altered 
pigmentation, moderate skin atrophy and pain. The response rate is around 51 to 74 
percent and may require more than one application (Thomas et al., 2002). 
 
New emerging therapies: Recently, a number of novel experimental therapeutic 
approaches have been explored, based on results from in vitro experiments from cells 
derived from keloid tissue [eg. Interferon γ (Granstein et al., 1990; Larrabee et al., 1990), 
imiquimod (Berman et al., 2002), 5-fluorouracil (Manuskiatti et al., 2002 ; Fitzpatrick et 
al., 1999), bleomycin (Yamamoto et al., 2006). 
 
Although new treatment modalities are constantly been explored, most of them are 
accepted on a broad consensus rather than backed by a good knowledge of the 
pathogenesis of keloid and hypertrophic scars. Adding to the problem, there is an evident 
shortage of randomized controlled trials to assess the efficacies of existing therapeutic 
interventions. It is also not possible to incorporate variables which widely exist among 
the patients in actual clinical setting, like differences in age, race, involved body part, 
associated systemic diseases like diabetes, local infection, in a volunteer-based study 
using artificial methods of induction of wound. Results based on animal/animal cell 
studies may not be reliable because animal tissue/cell behaviors are much different from 
that of humans and more over, diseases like keloid exclusively occur in humans. These 
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limitations make the assessment and comparison of different treatment methods very 
difficult.  
 
Thus, for more effective and specific treatments, it is imperative that molecular 
mechanisms that cause keloid formation are elucidated and better understood. Increased 
understanding at each level of pathogenesis may lead to development of new therapies, in 
form of synthetic drugs or specific growth factors, to downregulate profibrotic molecules. 
Monoclonal antibodies, growth factor receptor antagonists, antisense oligonucleotides are 
some of the treatment modalities that hold promise.  
 
1.3  OBJECTIVES OF THE PRESENT STUDY 
 
We hypothesise that epithelial–mesenchymal interactions have an important governing 
role in keloid formation, and that keloid formation may be the consequence of abnormal 
keratinocyte control over fibroblasts, mediated by the key factors like activin-A, 
proteoglycans, Stem cell factor , rather than a defect of fibroblasts themselves. 
 
 The broad objective of this study is to identify key modulators of cellular dynamics in 
keloid scars and investigate the effect of epithelial-mesenchymal interactions on the 
expression profiles of these modulators using various in vitro models. Depending on the 
profibrotic or antifibrotic effects of these modulators, they could either be targets for 
therapeutic intervention using chemical agents or themselves be used as natural 





The specific objectives of this study are as follows:  
 
1. To investigate the role of epithelial-mesenchymal interactions, especially 
fibroblast response to keratinocyte paracrine stimulation in wound contracture. 
 
2. To investigate the role of various growth factor systems in keloid pathogenesis  
a) Activin-A/ follistatin system 
b) Proteoglycans 
c) SCF/c-Kit system 
 
3. Finally to investigate both growth factors and synthetic agents which could be 
used as therapeutic agents for keloids 
a) Natural modulators: decorin, follistatin 














































2.1  MEDIA AND CHEMICALS 
 
Dulbecco’s modified eagle medium (DMEM), Hank’s balanced salt solution (HBSS), 
fetal calf serum (FCS), streptomycin, penicillin, gentamicin and fungizone were 
purchased from Gibco. Keratinocyte growth medium (KGM) was purchased from 
Clonetics (USA). Phosphate buffered saline without Ca2+ and Mg2+ (PBS), epidermal 
growth factor (EGF), cholera toxin and hydrocortisone were purchased from Sigma 
Chemical Co (USA). Dispase II was purchased from Boehringer Mannheim (USA). 
Rhodamine counter stain was obtained from Difco (USA). Tris base was purchased from 
J.T Baker. Triton X-100, ethylenediaminetetraacetic acid (EDTA), 30% acrylamide/bis 
solution (37.5:1 2.6%C) and glycine were purchased from Biorad. Sodium Chloride 
(NaCl), nonidet P-40 (NP-40), sodium dodecyl sulphate, hydrogen peroxide (H2O2), 
bovine serum albumin (BSA), tween-20, potassium chloride (KCl), potassium phosphate 
(K3PO4), magnesium chloride (MgCl2), MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide], N,N –dimethylformamide (DMF) and paraformaldehyde 
were all purchased from Sigma Chemical Co (USA). Methanol and acetic acid were 
purchased from Lab-Scan. 
  
2.2  RECOMBINANT GROWTH FACTORS AND ANTIBODIES 
 
Mouse anti-α- SMA monoclonal antibody (Sigma), mouse anti-TGF- β1 neutralizing 
antibody (R&D systems), Mouse anti-Collagen I,III monoclonal antibody 
(Monosan®antibodies-The Netherlands), rabbit anti-fibronectin monoclonal antibody 
(BD Transduction Laboratories), mouse anti-activin-A monoclonal antibody (Oxford 
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Bio-Innovations, Oxford, UK) and mouse anti-follistatin (Gift from Dr David Phillips, 
Monash University, Melbourne, Australia), rabbit-anti syndecan-2 polyclonal antibody 
(Santa Cruz Biotechnology), rabbit-anti FGF-2 polyclonal antibody (Santa Cruz 
Biotechnology), mouse anti-decorin monoclonal antibody (R&D systems), rabbit-anti 
TACE polyclonal antibody (Santa Cruz Biotechnology), rabbit anti-c-Kit (tyr 703) 
polyclonal antibody (Affinity BioReagents), rabbit-anti c-Kit (tyr 721) polyclonal 
antibody (Affinity BioReagents), mouse-anti c-Kit monoclonal antibody (Neomarkers), 
mouse-anti c-Kit monoclonal antibody (R&D systems), rabbit-anti VEGF polyclonal 
antibody (Neomarkers), HDGF (Gift from M.D Anderson Cancer Center, U.S) , mouse-
anti Phospho Akt (Cell signaling), mouse-anti Phospho mTOR (Cell signaling), Labeled 
chicken- anti mouse IgG antibody (Molecular probes), goat-anti rabbit IgG H&L (HRP) 
polyclonal antibody (abcam), rabbit-anti mouse IgG H&L (HRP) polyclonal antibody 
(abcam), rabbit-anti mouse IgM H&L (HRP) polyclonal antibody (abcam), recombinant 
human activin-A (R&D systems), recombinant human follistatin (R&D systems), 
recombinant human decorin (R&D systems), recombinant human TGF-β1 (R&D 
systems), recombinant human FGF-2 (R&D systems). 
 
2.3 PREPARATION OF NORMAL AND KELOID TISSUE                    
EXTRACTS 
 
Normal and keloid skin tissues were cut into small pieces using a scalpel to about 120 
mg.  200 µl of lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1% v/v Triton X-100, 
100 mM NaCl, 0.5% w/v Nonidet P-40 and 1mg/ml protease inhibitor cocktail 
(Boehringer Mannheim, Mannheim, Germany) were added to the tissue sections and 
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sonicated. This was followed by centrifugation at 13000 x g for 10 min. Supernatant was 
collected while the pellet was discarded. Protein concentration of the tissue extracts were 
determined by the Bradford method. 
 
2.4  IMMUNOHISTOCHEMISTRY 
 
2.4.1 Preparation of Paraffin Sections of Normal and Keloid Tissues 
 
Normal and keloid tissue samples were fixed in 4% v/v formalin in PBS for 24 hr (longer 
for larger samples but never more than a week) followed by immersion in 70% v/v 
ethanol overnight, in histocassettes. This was followed by paraffin embedding as per 
standard protocol (BD biosciences). Sections were cut at 5 microns onto slides.     
Tissue sections were dried onto the slides at 37 oC overnight. 
2.4.2 Pretreatment of Paraffin Sections for Immunohistochemistry 
 
The paraffin sections were dewaxed or deparaffinized in two changes of xylene followed 
by re-hydration at 100%, 95% and 70% v/v ethanol gradients. The antigens were then 
retrieved by immersing slides in 0.01 M citrate buffer, pH 6.0, heating in a microwave 
oven (high for 2.5 min, low for 5 min), cooling at 4°C for 20 min, and washing in water 
for 5 min. Endogenous peroxidase was blocked in 3% v/v H2O2, and non-specific binding 





2.4.3  Probing with Antibody and Developing 
 
Sections were then incubated in specific antibodies for 1-2 hrs at room temperature. After 
washing, slides were incubated in universal secondary antibody provided in the vectastain 
kit (Vector Labs). Slides were washed in Tris-buffered NaCl (TBS) 0.05% w/v Tween-20 
pH 7.5, then MilliQ H2O. The sections were then treated with “vectastain elite RTU elite 
reagent” for five minutes. The reaction product was developed with a 3, 3’-
diaminobenzidine tetrahydrochloride substrate kit (Dako), and sections counterstained 
with hematoxylin. All wash steps were in TBS/0.05% w/v Tween-20. Antibodies were 
diluted in 1% w/v BSA/TBS. 
 
2.5  CELL CULTURE 
 
2.5.1 Keloid Keratinocyte and Fibroblast Database 
 
Keratinocytes and fibroblasts were randomly selected from a specimen bank of 
keratinocyte/fibroblast strains derived from excised keloid specimens. All patients had 
received no previous treatment for keloids before enrollment. Before informed consent 
was obtained, a full history was taken and an examination performed, complete with 
photographic documentation. The tisssues were separated into normal and keloids by an 
approved surgeon and pathologist. Approval by the National University of Singapore-





2.5.2 Keloid and Normal Keratinocytes from Keloid scar and Normal Skin 
 
Excised keloid scar and normal skin specimens were repetitively washed in PBS 
containing 150 µg/ml gentamicin and 7.5 µg fungizone, until the washing solution 
became clear. The tissue was then divided into pieces of approximately 5 mm × 10 mm 
and the epidermis was scored. Dispase 5mg/ml in HBSS was added and skin was 
incubated overnight at 4ºC. The epidermis was carefully scraped off with a scalpel the 
next day and placed in trypsin 0.25% w/v /glucose 0.1% w/v /EDTA 0.02% for 10 min in 
the incubator. Trypsin action was quenched by DMEM/10% FCS. The suspended cells 
were transferred into tubes and centrifuged at 1000 rpm for 8 min. The cells were seeded 
in Keratinocyte Culture Medium (80 ml DMEM supplemented with 20 ml FCS, EGF 10 
ng/ml, cholera toxin 1 × 10-9 M and hydrocortisone 0.4 µg/ml) at 1 × 105 cells/cm2 for 24 
hrs before changing to Keratinocyte Growth Medium (KGM). The cell strains were 
maintained and stored at -150ºC. Only cells from second and third passages were used for 
the experiments. 
 
2.5.3 Keloid and Normal Fibroblast from Keloid Scar and Normal Skin 
 
Remnant dermis from the keloid scar and normal skin were either minced or incubated in 
a solution of collagenase type 1 (0.5 mg/ml) and trypsin (0.2 mg/ml) at 37ºC for 6 hrs. 
Cells were pelleted and grown in tissue culture flasks. Alternatively the skin tissue 
samples were chopped into pieces of 1-2 mm2. The pieces were then transferred to a 100 
mm tissue culture dish previously coated with a thin layer of DMEM/10% v/v FCS. 
Culture medium enough to cover the explants were then added and topped up after 2-3 
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days. After 4-7 days the fibroblasts outgrew from the tissue. Fibroblast cell strains were 
maintained and stored at -150ºC until use. Only cells from the second and third passages 
were used for the experiments. 
 
2.5.4 Keratinocyte-fibroblast Coculture 
 
 
KK obtained from randomly selected keloid strains were seeded at density of 1 × 105 
cells/cm2 on 6-well transwell clear polyester membrane inserts with 0.4 µm pore size and 
area 0.3 cm2 area (Costar Corp, USA). Ten days before co-culture, cells were maintained 
in serum-free Keratinocyte Growth Medium (KGM) until 100% confluent in monolayer. 
The medium was then changed to Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat inactivated fetal bovine serum (FBS) and 
penicillin/streptomycin. The cells were raised to air-liquid interface to allow 
keratinocytes to stratify and reach terminal differentiation.  
 
KF obtained from randomly selected keloid strains were seeded in 6-well plates at a 
density of 1 × 104 cells/ml in DMEM/10% v/v FCS for 24 hrs and then in serum-free 
medium for another 48 hrs. Cells on both the membrane inserts and the wells were 
washed twice with phosphate buffer saline (PBS) to remove the old medium before 
combination of the inserts and plates for co-culture in serum-free DMEM. Controls 
comprised of one series of non co-cultured keloid fibroblasts and one series non co-
cultured keloid keratinocytes. At day 5, the inserts with the cultured keratinocytes were 
removed, and the conditioned media were collected, pooled and stored at -80ºC for later 
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analysis. The fibroblasts and keratinocytes were also harvested for protein extraction for 
western blot analysis. (Fig. 5) 
 
Figure 5: Coculture of epidermal keratinocytes and dermal fibroblasts as an in vitro model 














Fibroblast subculture Keratinocyte subculture 
Keratinocyte- Fibroblast Coculture  
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2.6  CELL COUNTING 
 
Before the cells were seeded into culture flasks for experiments, aliquots of the cell 
suspension were mixed with trypan blue in a ratio of (1:4) and counted in a Neubauer’s 
haemocytometer. All the cells (non-viable cells stained blue, viable cells became opaque) 
were counted in the four corner squares of the hemocytometer. Since the volume of each 
square is 10-4 cm3 use the following formula was used to calculate the number of cells in 
the cell suspension  
Cells per ml = the average count per square x the dilution factor x 104 
Total cell number = cells per ml x the original volume of fluid from which cell sample 
was removed. 
 
2.7  TREATMENT OF FIBROBLASTS WITH GROWTH FACTOR 
 
NF and KF from different patients were seeded in 6-well plates at a density of 1 × 104 
cells/ml in DMEM/10% v/v FCS for 24 hrs and then in serum-free medium for another 
48 hrs. The cells were subsequently treated with varying concentrations of activin-A (100 
ng/ml; (R&D Systems), follistatin (FS-288, 100 ng/ml; R&D Systems) or TGF-β1 (5, 10 
ng/ml; R&D Systems), decorin (0, 250, 500, 1000, 2000 ng/ml; R&D Systems), FGF-2 
(10 ng/ml; R&D Systems) respectively, to test the effect of these growth factors on the 
proliferation of fibroblasts and expression of key ECM proteins. 
 
 
2.8  TREATMENT OF CELLS WITH GLEEVEC 
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NF and KF from different patients were seeded in 6-well plates at a density of 1 × 104 
cells/ml in DMEM/10% v/v FCS for 24 hrs and then in serum-free medium for another 
48 hrs. The cells were subsequently treated with varying concentrations of gleevec (0.5 
µg/ml, 1 µg/ml, 2.5 µg/ml, 5 µg/ml, 10 µg/ml, and 20 µg/ml), to test its effect on the 
proliferation of fibroblasts and expression of key ECM proteins. 
 
2.9   SERUM STIMULATION 
 
When fibroblasts are exposed to serum, the signal is interpreted to be a physiological 
wounding signal. The serum stimulation model is an in-vitro model used to mimic the 
early phases of wounding. NF and KF were seeded in 6-well plates at a density of 1 × 104 
cells/ml in 10% v/v FCS for 24 hrs and subsequently seeded in serum-free medium for 
another 48 hrs. The fibroblasts were exposed to either DMEM supplemented with 10% 
v/v FCS or DMEM alone for 24 hrs before being harvested for analysis. 
 
2.10  MTT ASSAY 
 
The MTT assay is a commonly used colorimetric assay to quantify cell numbers. It is 
widely used in studies involving cell proliferation or cell toxicity. MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] is cleaved by an active succinate-
tetrazolium reductase system present in the mitochondrial respiratory chain of a living 
and metabolizing cell into blue formazon crystals which can be solubilized and 
absorbance measure. The relationship between cell number and absorbance is linear. 
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In our experimental set up, the treated cells in 96-well plates were incubated with 10 µl of 
MTT (5 mg/ml) in 100 µl of DMEM to give a final concentration of 0.5 mg/ml in each 
well for about 2hrs. The medium was removed and the blue crystals were soubilized by 
Hansen’s method (1989) using 20% w/v SDS in a solution of DMF: water (1:1 v/v) and 
shaking in an orbital shaker. The absorbance of the solution was then measured directly 
by using a plate reader at 570 nm. 
  
2.11  FIBROBLAST-POPULATED COLLAGEN LATTICE (FPCL) 
 
2.11.1 Preparation of Fibroblast-Populated Collagen Lattices 
 
Collagen lattices were prepared from type 1 collagen extracted from rat tail tendons in 
0.1% (v/v) acetic acid. A working solution was constituted by diluting the collagen to 1.6 
mg/ml on the day of experiment. Both NF and KF cell strains were trypsinised, 
resuspended in medium and counted using a hemocytometer. A collagen-fibroblast (for 
both NF and KF) suspension was prepared in serum-free DMEM and 2 ml of the 
suspension was dispensed into 32-mm petri dishes. The final concentration of collagen 
was 0.8 mg/ml with a cell density of 6.7 × 104 cells/ml. The collagen lattices were 






2.11.2  Macroscopic Evaluation of FPCL Contraction 
 
The lattice diameters were assessed at various time-points for several days by placing the 
dish on transparent graph paper and measuring two diameters at right angles to one 
another. The area of collagen gel populated with fibroblasts was photographed. The 
average area was calculated from the mean of the diameters and expressed as a 
percentage of initial lattice area. 
 
Percentage of initial area = A2/A1 × 100, 
 
where A1 = initial gel area and A2 = area at the observed interval 
 
2.12    WESTERN BLOTTING 
 
To study the changes in the expression of investigative proteins in keratinocytes and 
fibroblasts under different culture conditions and under treatment with different drugs, 
cells were lysed in lysis buffer containing 20 mM Tris-HCL (pH 7.5), 1% v/v Triton X-
100, 100 mM NaCl, 0.5% w/v Nonidet P-40 and 1 mg/ml protease inhibitor cocktail 
(Antipaindihydrochloride, Aprotinin, Bestatin, Chymostatin, E-64, EDTA-Na, Leupeptin, 
Pefabloc-SC, Pefstatin, Phosphormidon; Boehringer Mannheim, Mannheim, Germany). 
100 µg of protein was extracted and electrophoresed on 8% w/v and 14% w/v sodium 
dodecyl sulphate-polyacrylamide gels using the Protein II system (Bio-Rad). The proteins 
were subsequently transferred to a nitrocellulose membrane and blotted for antibodies 
against the proteins under investigation. This was followed by treatment with respective 
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secondary antibodies.  The blots were then visualized with a chemiluminescence-based 
photoblot system (Amersham Biosciences). 
 
2.13  IMMUNOASSAY 
 
An immunoassay is a biochemical test generally used to measure the level of antigens 
present in a biological fluid like serum or urine. It has an advantage of being highly 
specific as well as sensitive. Due to this reason, often very low volume of sample is 
required to detect the antigen. 
  
In our study, ELISA kits for detection of investigative proteins were purchased and 
assays performed on conditioned media (100 µl) obtained from NF, NK, KF and KK. 
 
2.14  FLOW CYTOMETRY 
 
FACS analysis was performed to detect the investigative protein’s expression. Briefly, 
about 5*105 to 1*106cells were washed twice with ice-cold PBS at 250 g for 5 min. The 
cells were then incubated with antibodies against the proteins for 30 min at 4°C followed 
by incubation with an FITC-conjugated secondary antibody in for 30 minutes at 4°C in 
the dark.  Cells treated with an isotype control or without primary antibody were used as 
negative controls. All washing steps involved washing with flow cytometry buffer 
containing PBS, 2% v/v FBS and 0.1% v/v sodium azide. Thereafter, the cells were fixed 
in 2% w/v paraformaldehyde in PBS for 15 minutes at 4°C in the dark. A FACScan 
(Becton Dickinson, Sunnyvale, CA) flow cytometer was used for the analysis. 
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2.15  RNase PROTECTION ASSAY 
 
The RNase protection assay is a highly sensitive method used to detect and quantify 
specific mRNA transcripts in a mixture of total RNA or mRNA. The assay involves 
hybridising a radioactive probe complementary to the gene sequence of interest, and then 
adding RNase to the mixture. The RNase digests the entire single stranded RNA leaving 
behind the double stranded probe-target hybrid. This hybrid is then electrophoresed on a 
denaturing TBE-urea polyacylamide gel and detected. 
 
In this study, the total RNA was isolated from the tissue lysate. RNase protection assay 
was performed as described by Werner’s group (1993) using a radiolabelled antisense 
probe complementary to the activin-βA mRNA (Hübner et al., 1996). Hybridization of 
the same RNA with a gapdh riboprobe served as a loading control. 
 
2.16  RATE OF ATP SYNTHESIS 
 
The measurement of ATP by the luciferin-luciferase reaction was done as previously 
described. (Vincent et al., 2004; Zhang et al., 2004) and was extended in this study to 
digitonin-permeabilized whole fibroblasts. KF were permeabilized with 65 µg 
digitonin/106 cells in buffer (150 mM KCl, 25 mM Tris-HCl, 2 mM EDTA, 0.1% w/v 
BSA, 10 mM potassium phosphate, 0.1 mM MgCl2, pH 7.4).  The reaction mixture 
contained 1 mM ADP in a total volume of 0.25 ml of the above buffer.   The reaction was 
started with 50,000 cells, treated with the drug or only treated with DMEM with 5% v/v 
serum for 24 hrs, followed by incubation at 37oC for 5 min and stopped by boiling for 3 
min.  Following centrifugation, 25 µl supernatant was added to a well in a 96-well plate 
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together with 100 µl of 250x-diluted FL-AAM (Sigma). The chemiluminescence 
generated was read in a luminometer (PerkinElmer Victor) as described previously by 
Ng’s group (2006). The amount of ATP biosynthesized in 5 min was extrapolated from a 
standard curve of ATP of 5 to 100 ρmol, a range which produced a linear response.  
 
2.17  MEASUREMENT OF INTRACELLULAR ATP  
 
 
Intracellular ATP was determined from the whole cell lysate following the luciferin-
luciferase assay described above. Normalization was done with the protein content of the 
lysate determined by the Bradford method. 
 
2.18  STATISTICAL ANALYSIS 
 
 
Statistical significance between groups was assessed using either Student’s t-test or a 
one-way analysis of variance with Tukey’s post-hoc test. All tests were performed using 
MiniTab® software. Except  for ELISA measurements where the mean value of data 
from 5 different cell populations in each group was used, for all other results the cell 
population representative of other populations with at least 5 different clinical samples 
studied was conducted.  Differences at the 95% level ( P value < 0.05) were considered to 















3 ROLE OF EPITHELIAL-MESENCHYMAL 





















3.1  INTRODUCTION 
 
 
The process of wound contraction, which involves the centripetal movement of the 
wound edges by means of a retractile activity of the granulation tissue, is very critical for 
proper healing of any cutaneous wound. However, unlike in other mammals, the 
contraction of wound is often less beneficial in humans leading to minimal scarring in 
some cases to major body deformations (Hunt et al., 1979; Rudolph et al., 1992). 
Although it is widely accepted that the contractile force resides in the granulation tissue 
which fills the wound (Carell et al., 1916), the exact mechanism is still not clearly 
understood.  
Epithelial-mesenchymal interactions have recently been explored as a possible factor 
contributing to excessive scar formation. Given their emerging role in keloid 
pathogenesis ((Lim et al., 2001; 2002; 2003; Funayama et al., 2003; Xia et al., 2004) 
they might well be an important player in modulating wound contraction and scar 
contracture. During wound contraction, fibroblasts differentiate into myofibroblasts 
expressing α-smooth muscle actin. In normal wound repair, these myofibroblasts undergo 
apoptosis and disappear but under pathological conditions these myofibroblasts become 
apoptosis resistant, remain in the extracellular matrix and continue to remodel, leading to 
sustained wound contracture (Tomasek et al., 2002). Previous studies reported the 
modulation of underlying mesenchymal cell apoptosis by the epithelium (Hurle et al., 
1986). It has been further reported that epithelial–mesenchymal interaction upregulates 
TGF-β1 (Funayama et al., 2003; Xia et al., 2004), a growth factor with important roles in 
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wound and scar contraction (Kamamoto et al., 2003; Spyrou et al., 2002). In addition, 
TGF-β has also been found to inhibit apoptosis of different types of cells including 
myofibroblasts (Smith et al., 1999; Kim et al., 1998; Genestier et al., 1998) by various 
mechanisms including the downregulation of c-myc, preventing the decline of Bcl-2 
(Zhang et al., 1999) and through activation of the protein kinase pathway (Chin et al., 
1999). Taken a step further, epithelial-mesenchymal interactions would similarly affect 
wound contracture by modulating apoptosis of myofibroblasts. The exact mechanism for 
this however remains unclear. 
New investigative tools, arising from tissue bioengineering have stimulated new studies 
related to scar formation. Bell’s group (1979) described an in vitro model for the study of 
wound contraction using collagen gels populated by fibroblasts. The advantage of this 
model is that it includes the two fundamental dermal participants in scar formation: the 
ECM and the fibroblasts, unlike the traditional in vitro models where the cells are grown 
as a monolayer. Harris and co-workers (1981) demonstrated that the contraction of the 
collagen lattice occurred as a consequence of fibroblast migration through the matrix. 
This process was termed ‘tractional remodeling’ (Grinell et al., 1994). 
 
In this study, we hypothesized the role of epithelial-mesenchymal interactions, especially 
fibroblast response to keratinocyte paracrine stimulation in wound contracture. To test 
our hypothesis, we investigated the contractile response of collagen lattices populated by 
KF and NF, respectively to the addition of conditioned media obtained from KK/KF 
coculture. To complement this data, immunohistochemical analysis of the fibroblasts 
exposed to KK/KF conditioned media was performed to assess the expression of alpha-
smooth muscle actin in order to test our second hypothesis that fibroblasts exposed to this 
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abnormal media might differentiate into the myofibroblasts in keloid scar tissue. The 
effect of anti-TGF β1 neutralizing antibody on collagen lattice contraction induced by 
KK/KF coculture conditioned media was also studied to investigate the role of this 
fibroinductive cytokine. 
 
3.2  RESULTS 
 
 
• Keloid or normal dermal fibroblast populated collagen lattice exhibited 
significant contraction when treated with KK/KF coculture conditioned media 
 
Study groups comprised collagen matrices populated with KF or NF exposed to the 
conditioned media collected from KK/KF coculture or non-cocultured KKs (KK48, 
KK43, KK30, KK25) or KFs (KF48, KF43, KF30, KF25). Lattice areas were calculated 
at intervals of 1, 2, 3, 6, 24 and 48 hrs to determine the contraction percentage. 
Conditioned media from the non-cocultured KK and non-cocultured KF controls induced 
slight contraction of collagen lattices populated by KFs (Fig. 6a), but no contraction in 
the group of collagen lattices populated with normal dermal fibroblasts (Fig. 6b). 
Conditioned media obtained from KK/KF coculture, however, induced significantly 
greater collagen lattice contraction, with nearly 90% or 60% contraction of the collagen 
gel at 48 hrs compared with approximately 20% or 5% contraction for the controls, with  





• Contraction of collagen lattice populated by KF was more significant as 
compared to that populated by NF 
 
The FPCLs were photographed and the area calculated as previously mentioned, for side-
by-side analysis. It was observed that collagen lattices populated with KFs demonstrated 
significantly greater contraction when treated with KK/KF conditioned media compared 
with collagen lattices populated with NF (Figs 6 and 7) 
 
• Expression of α-smooth muscle actin was increased in keloid-derived fibroblasts 
treated with keloid keratinocyte/keloid fibroblast coculture conditioned media 
 
KF and NF were seeded at a density of 1000 cells per well in eight-well Laboratory-tek 
chamber slides in DMEM/10% FCS for 24 hrs. The medium was then replaced by serum-
free DMEM for 48 hrs. After 48 hrs, conditioned media pooled from KK/KF coculture 
and non-coculture samples were added. This was followed by addition of anti-α-SMA 
antibody (Sigma, A-2547). A rhodamine counterstain (Difco) was added to the 
fluorescein isothiocyanate-labelled secondary antibodies to reduce the nonspecific 
background staining. A bright green fluorescence marked the positive expression of α-
SMA, while cells demonstrating minimal or no expression were stained dull orange. 
Compared with control groups treated with non-coculture conditioned media, increased 
expression of α-SMA (marked by bright green fluorescence) was seen in both KF 
(Fig. 8a) and NF (Fig. 8b) study groups treated with conditioned media obtained from 
KK/KF coculture. Actin fibres were more elongated and stressed in the cells treated with 
KK/KF coculture conditioned media compared with those treated with non-coculture 
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conditioned media. KFs demonstrated significantly increased expression of α-SMA 
compared with similarly exposed NF (Fig. 8). 
 
• Contraction of KF populated collagen lattice by KK/KF coculture conditioned 
media is attenuated by anti-TGF-β1 neutralizing antibody. 
 
Study groups comprised collagen matrices populated by KFs from sample KF48 with 
conditioned media collected from KK48/KF48 coculture, non-cocultured KKs, non-
cocultured KFs and KK48/KF48 coculture with anti-TGF-β1 antibody. At each interval 
(6, 24 and 48 hrs) the percentage lattice contraction was calculated. Significant 
contraction was seen in collagen lattice exposed to conditioned medium obtained from 
KK/KF coculture compared with non-coculture samples. The addition of anti-TGF-β1 
antibody to the conditioned medium obtained from KK/KF coculture, however, 












Figure 6: Effect of conditioned media collected from (KK)/(KF) cocultures on collagen 
contraction by KFs 
Collagen matrices composed of KFs (a) or NFs (b) were treated with conditioned media collected 
from non-cocultured KKs ,non-cocultured KFs (□) and KK/KF coculture (■). At each interval of 
study (1, 2, 3, 6, 24 and 48 h) the area of the gel was calculated as a percentage of the initial area. 
Each bar shows mean ± SEM of eight lattices pooled from four independent experiments using 








Figure 7: Comparison of contraction of collagen gel lattice incorporated with KFs and NFs. 
The fibroblast-populated collagen lattices were collected after 48 hrs, stained with rhodamine B 
and photographed. (a) NF1 and (b) KF48 were treated with KK48/KF48 coculture conditioned 
media. (c) NF2 and (d) KF30 were treated with KK30/KF30 coculture conditioned media. 
(e) NF3 and (f) KF25 were treated with KK25/KF25 coculture conditioned media. (g) NF4 and 









Figure 8: α-Smooth muscle actin (α-SMA) expression by KFs (a) or NFs (b).  
KFs (a) and NFs (b) were seeded at a density of 1000 cells per well in eight-well Lab-tek 
chamber slides in Dulbecco's modified Eagle's medium (DMEM)/10% fetal calf serum for 24 hrs. 
Medium was then replaced by serum-free DMEM for 48 hrs. After 48 hrs conditioned media 
pooled from keloid keratinocyte (KK)/KF coculture and non-coculture samples were added. This 
was followed by addition of anti-α-SMA antibody. A rhodamine counterstain was added to the 
fluorescein isothiocyanate-labelled secondary antibodies at a 1: 40 dilution. A bright green 
fluorescence marked the positive expression of α-SMA, while cells demonstrating minimal or no 
expression were stained dull orange. Each set represents KFs (a) or NFs (b) treated with 







Figure 9: Effect of anti transforming growth factor (TGF)-β1 neutralizing antibody on 
collagen contraction by KF48 induced by conditioned media collected from KK48)/KF48 
coculture.  
Collagen matrices composed of KF48 were treated with conditioned media collected from 
KK48/KF48 coculture (checked ■), KK non-coculture (■), KF non-coculture (□) or KK48/KF48 
coculture with anti-TGF-β1 antibody (  ). At each interval of study (6, 24 and 48 hrs) the area of 
















3.3  DISCUSSION 
 
 
In recent years, significant work has been done to support the hypothesis that epithelial–
mesenchymal interactions have an important governing role in keloid formation, and that 
keloid formation may be the consequence of abnormal keratinocyte control over 
fibroblasts rather than a defect of fibroblasts themselves (Yang et al., 2003). In this study 
an established two-chamber coculture model was used to obtain conditioned media and 
the effects of the latter was tested on FPCLs, an established three-dimensional wound 
contraction and scar contracture model, to investigate the effect of paracrine secretions 
from epithelial–mesenchymal interactions on collagen lattice contraction. Conditioned 
media obtained from KK/KF coculture induced greater and faster contraction of collagen 
lattices populated with KFs compared with lattices populated with NFs. It was also 
observed that conditioned media obtained from non-cocultured KFs and KKs produced 
decreased contraction of the collagen lattice. This underscores the importance of 
paracrine secretions resulting from epithelial–mesenchymal interactions in wound repair, 
and supports the role of overlying epidermal keratinocytes in modulation of KF 
behaviour. 
 
Transforming growth factor-beta has often been considered to be a key player in the 
pathogenesis of keloids (Kim et al., 2000). Increased mRNA expression of TGF-β1 and 
collagen has been observed in keloids (Kim et al., 2000). Previous studies demonstrated 
that KFs produced increased TGF-β (Fusenig et al., 1994; Maas-Szabowski et al., 1999; 
Mackenzie et al., 1994). Tissue fibrosis is thought to be the result of excessive ECM 
deposition induced by TGF-β which signals fibroblasts to increase the synthesis of matrix 
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proteins, decrease the production of matrix-degrading proteases and increase the 
production of inhibitors of these proteases (Border et al., 1996). There is evidence 
suggesting that TGF-β1 can inhibit apoptosis in various types of cells (Smith et al., 1999; 
Kim et al., 1998; Genestier et al., 1998). Chodon’s group (2000) reported that 
dysregulation in the Fas-mediated apoptosis which occurs in normal wound healing may 
be a factor contributing to scar formation and suggested a role for TGF-β1 in this 
resistance; specifically that of prolonged proliferative phase due to generation of  an 
apoptosis resistant phenotype. As the epithelium regulates underlying mesenchymal cell 
apoptosis (Hurle et al., 1986), epithelial-mesenchymal interactions could be one factor 
responsible for this decreased apoptosis. Funayama and his co-workers (2003) 
demonstrated through a similar coculture model that the keloid derived fibroblasts 
brought about a greater proliferation and diminished apoptosis when cocultured with NK 
and KK. They also demonstrated an upregulation of TGF-β1 in the fibroblasts cocultured 
with keloid derived keratinocytes.  Xia and his team (2004) demonstrated that the 
upregulation of TGF-β1 in a previous study and observed that this was the net effect of an 
increased TGF-β1 mRNA transcription in response to paracrine signaling between KK 
and KF which was amplified in keloid versus normal cells. Their group postulated that an 
aberration in this paracrine regulation in Keloid-derived cells could have resulted in the 
generation of a positive feedback loop between KKs and KFs even after reepithelisation, 
increasing the expression of TGF-β1 and related factors such as CTGF, which potentiate 
TGF-β signaling. 
 
TGF-β1 has also been demonstrated to enhance the contraction of collagen gels in vitro 
(Montesano et al., 1998; Finesmith et al., 1990) and wound contraction in vivo 
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supporting its role in wound contraction. The effect of TGF-β is mainly through the Smad 
family of proteins, although a Smad independent pathway involving signaling through 
MAPK, ERK, JNK pathways has also been proposed (Derynck et al., 2003). In the 
present study, we observed attenuation of FPCL contraction with the addition of anti-
TGF-β1 neutralizing antibody into conditioned media from KK/KF co-culture, indicating 
the importance of TGF-β1 in keloid scar contracture. 
 
Myofibroblasts, a group of actin rich fibroblasts, are known to play an important role in 
wound contraction. Wound contraction is a very important step in wound repair involving 
the conversion of proto-myofibroblasts to differentiated myofibroblasts by the production 
of α-SMA in order to generate more force for contracture (Tomasek et al., 2002; Roy et 
al., 2001). In normal wound repair, these myofibroblasts disappear by apoptosis but in 
pathological conditions the myofibroblasts persist and continue to remodel the ECM, 
resulting in connective tissue contracture (Tomasek et al., 2002). Since increased 
expression of TGF-β1 directly induces α-SMA expression (Desmouliere et al., 1993; 
1995; Ronnov-Jessen et al., 1993) and epithelial–mesenchymal interactions modulate 
TGF-β1 expression, we hypothesized that epithelial–mesenchymal interactions could also 
indirectly modulate α-SMA expression in vitro. In the present study 
immunohistochemical analysis of α-SMA expression by KFs and NFs exposed to 
conditioned media from KK/KF coculture and non-coculture conditioned media controls, 




To summarize, it has been demonstrated that the paracrine output from epithelial-
mesenchymal interactions between KKs and KFs modulate contraction of FPCL, strongly 
suggesting its role in scar and wound contraction. TGF-β1 is likely to play an important 
role in contraction of FPCL induced by epithelial-mesenchymal interactions. These data 
suggest a therapeutic approach involving targeting the epidermal layer of the keloid 





































4.1  INTRODUCTION 
 
The bioactivity of fibroblasts in fibrogenesis or excessive scar formation is regulated by a 
number of growth factors. The transforming growth factor-β (TGF-β) family, comprising 
the TGF-β’s, bone morphogenetic proteins (BMPs) and activins, is thought to play a 
central role by regulating fibroblast proliferation, differentiation and matrix production 
(Derynck et al., 2003; Kim et al., 2000; Niessen et al., 1999; Tuan et al., 2000). Although 
a series of studies has demonstrated the importance of TGF-β as a key player in keloid 
pathogenesis, the function and role of activin-A have yet to be established. 
 
Activins, like other members of the TGF-β superfamily, are dimeric proteins consisting 
of two βA subunits (activin-A), two βB subunits (activin-B) or a βA and a βB subunit 
(activin-AB) (Massague et al., 1990; Vale et al., 1990). Activin-A signals through 
heterodimeric complexes of two receptor types - type I receptors, also called activin 
receptor-like kinases (ALKs), and type II receptors which are transmembrane serine–
threonine kinases (Mathews et al., 1993). The biological action of activin-A is also 
regulated by follistatin, a soluble activin-binding glycoprotein, which inhibits activin’s in 
vitro and in vivo functions (Massague et al., 1990; Phillips et al., 2003). 
 
Activin-A was discovered initially as a regulator of pituitary function (Vale et al., 1986). 
Subsequent research has shown it to affect proliferation and differentiation of various cell 
types. For example, it has been shown to stimulate proliferation of lung fibroblasts and 
their differentiation into myofibroblasts (Ohga et al., 1996). It has also been 
demonstrated to play a role in the proliferation and differentiation of keratinocytes in 
vitro (Seishima et al., 1999). Activin-A inhibits proliferation of vascular endothelial cells 
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(Mathews et al, 1994; McCarthy et al., 1993; Kozian et al, 1997) and has been shown to 
cause cell death in primary hepatocyte cultures (Schwall et al., 1993), B cell hybridomas 
and mouse and human myeloma cells (Nishihara et al., 1993, 1995). 
The first evidence for a role of activin-A in wound healing came from the studies by 
Hübner’s group (1996). They demonstrated an increased induction of activin-A 
expression within 24 hr after injury, which remained high until the end of the repair 
process. Transgenic mice, which overexpressed the activin-βA subunit specifically in the 
epidermis, had epidermal hyperthickening and dermal fibrosis (Munz et al., 1999). After 
skin injury, these mice showed enhanced granulation tissue formation with strong 
deposition of ECM below the hyperproliferative keratinocytes. By contrast, reduced 
granulation tissue formation and thus delayed healing was observed in mice 
overexpressing the activin antagonist, follistatin, in the epidermis (Wankell et al., 2000). 
 
Several studies have implicated activin-A as an important player in fibrotic disorders. 
Sugiyama’s team (1998) demonstrated an upregulation of activin-A in cirrhotic and 
fibrotic rat livers. Furthermore, there was an increased expression of activin-A in various 
pulmonary conditions associated with interstitial pulmonary fibrosis (Matsuse et al., 
1996). Activin-A has also been reported to act as a profibrotic cytokine in renal disease 
(Gaedeke et al., 2005). Thus, although in vitro studies suggest that activin-A may play a 
role in the repair of the mesenchyme and epithelium, a disruption in the control of 
activin-A expression could lead to the development of tissue fibrosis.  
 
The present study characterized the role of activin-A synthesis and signaling in keloid 
pathogenesis. It evaluated the activin-follistatin system in regulating cellular proliferation 
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and expression of ECM components in keloid scars, using an extensive array of 
techniques such as RNAse protection assay, immunohistochemistry, and co-cultures. 
Overall, the expression and production of activin-A and its biological regulator, 
follistatin, were perturbed in the development of human keloids. 
 
4.2  RESULTS 
 
 
• Increased activin-A and follistatin in the basal layer of epidermis in keloid 
tissues 
 
Immnohistochemical analysis on paraffin sections of normal skin tissues and keloid scar 
tissues was performed as previously mentioned. The sections were probed with 
antibodies against activin-A (Oxford Bio-Innovations, Oxford, UK) and follistatin (Gift 
from Dr David Phillips, Monash University, Melbourne, Australia) followed by 
secondary antibodies. Both activin-A and follistatin were found to be localized to the 
basal layer of the epidermis in both normal and keloid skins. However, an increased 
intensity of these proteins was observed in keloid tissues compared with normal skin 
tissues (Fig. 10). This suggested that the activin-follistatin regulatory system might be 
implicated in keloid pathogenesis. 
 
• Keloid scars expressed higher levels of activin-A mRNA compared with normal 
skin 
 
The expression profile of activin-A was studied using a RNase protection assay in keloid 
scars and normal skin tissues (Fig. 11). Normal skins and treated scars expressed very 
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low levels of activin-A mRNA. In contrast, keloid scar samples had abundant levels of 
activin-A mRNA.  
• Increased production of activin-A and follistatin by KF. 
NF and KF were cultured and conditioned media from these cultures were collected. 
Activin-A was measured in conditioned media samples using a specific enzyme linked 
immunosorbent assay (ELISA) (Knight et al., 1996) according to the manufacturer’s 
instructions (Oxford Bio-Innovations, Oxfordshire, UK) with some modifications for 
media samples as described previously (Buzzard et al., 2003). The average intra-plate % 
coefficient of variation (CV) was 8.1% (n = 4 plates) and the inter-plate %CV was 6.4%. 
The lower limit of detection was 0.01 ng/ml. Follistatin concentrations were measured 
using a discontinuous radioimmunoassay as described previously (O’Connor et al., 1999) 
with modifications for media samples. Conditioned media showed a linear dose-response 
curve which was parallel to the standard. The average intra-assay %CV was 7.7% (n = 3 
assays), the inter-assay %CV was 6.4% and the limit of detection was less than 1.94 
ng/ml. When cultured in isolation, KFs demonstrated a 29-fold higher secretion of 
activin-A compared with NFs (P < 0.0001; Fig. 12a). In contrast, NK produced 
significantly higher activin-A than KK (P < 0.0001; Fig. 12a). For follistatin, there were 
significant differences in secreted levels between KK and NK (P=0.019; Fig. 12b); KFs 
demonstrated a 5-fold increase in secreted levels of follistatin compared with NFs (P < 






• Over-expression of activin-A in HaCaT keratinocytes increased the proliferation 
of underlying fibroblasts during co-culture 
  
As the activin-follistatin regulatory system was shown to be upregulated in keloid tissues, 
we determined if HaCaT keratinocytes overexpressing activin-A (hβAHaCaT) modulated 
underlying fibroblasts in a paracrine manner. Normal human dermal fibroblasts 
cocultured with these overexpressing hβAHaCaT keratinocytes (Gift from Prof Sabine 
Werner, ETH, Zurich, Switzerland) demonstrated a 66% increase in proliferation 
compared with non-cocultured NFs (P < 0.0001; Fig. 13). In comparison NFs cocultured 
with neoHaCaT cells (cells transfected with the empty plasmid) (Gift from Prof Sabine 
Werner, ETH, Zurich, Switzerland) demonstrated only a 30% increase (P < 0.0001; Fig. 
13). 
 
• Activin-A increased proliferation in NFs and KFs and stimulated expression of 
ECM components 
 
Given that keratinocytes overexpressing activin-A stimulated the proliferation of 
underlying fibroblasts, the direct effect of activin-A on proliferation and ECM production 
were tested. Treatment of NFs and KFs with activin-A (100 ng/ml) resulted in a 23 % (p 
< 0.001) and 46% (p < 0.0001) increase, respectively, in proliferation compared with 
untreated controls (Fig. 14). This was comparable to the proliferation brought about by 
treatment with TGF-β1, although at a lower dose (10 ng/ml). 
 
It was then determined if activin-A and follistatin affected the production of ECM 
components like collagen, fibronectin and α-SMA in NFs and KFs. Using Western 
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blotting, an increase in collagen and α-SMA was observed in both NF and KF treated 
with activin-A compared with untreated cells (Fig. 15a, 15b, 15c, 15d, 15g, 15h). 
Elevated collagen and fibronectin levels in the conditioned medium in response to 
activin-A was confirmed in KFs (Fig. 15e, 15f). To assess the neutralizing ability of 
follistatin in this system, exogenous follistatin was co-administered with activin-A which 
resulted in a marked reduction in the expression levels of collagen and α-SMA. 
Follistatin treatment alone, unlike activin-A, significantly reduced the secreted levels of 
collagen, strongly suggesting that follistatin was blocking the stimulatory effects of 
endogenously produced activin-A (Fig. 15e). Activin when combined with TGF-β did not 
show significant difference in expression of both collagen and α-SMA when compared to 














Figure 10: Increased localization of activin-A and follistatin in the basal layer of epidermis 
in normal and keloid tissues.  
Paraffin sections of normal (a, b) and keloid (c, d) skin tissues were prepared and labeled with 
antibodies specific for activin-A (a, c) and follistatin (b, d) and observed with microscopy (100x). 
In each panel, the insert shows the same tissue labeled with a non-immune mouse antibody of the 
appropriate immunoglobulin isotype instead of the specific activin or follistatin antibody. Keloid 
tissues had more intense labeling in the basal layer of the epithelium compared with normal 
tissues. The localizations of activin-A and follistatin (or its lack in the negative control inserts) is 






























Figure 11: Expression of endogenous activin-βA mRNA derived from normal and keloid 
tissues.  
RNA was isolated from normal and keloid human tissues and analyzed by RNase protection assay 
for the presence of activin-A mRNA. Lanes 1, 2, 12: NS1, NS2, NS8 (normal skin). Lanes 3, 4, 5, 
6, 7: KS4, KS5, KS6, KS7, KS11 (keloid scars from burn patients). Lane 8, 9: Keloid treated-skin 











































Figure 12: Elevated levels of activin-A obtained from keloid fibroblast cultures 
Conditioned media obtained from NF (NF1,NF3,NF4,NF5,NF9), KF 
(KF16,KF31,KF32,KF43,KF48), NK (NK1,NK3,NK4,NK5,NK9) normal and KK 
(KK16,KK31,KK32,KK43,KK48) were assayed using immunoassays specific for activin-A (a) or 
















Figure 13: Increased proliferation of NF when cocultured with activin-A overexpressing 
hβAHaCaT cells 
Immortalized hβAHaCaT cells overexpressing the βA subunit of activin (striped bar) and 
neoHaCaT cells with only the resistance plasmid (solid bar) were co-cultured with normal NF. 
The control cultures (open bar) comprised of non-cocultured KF. Data are means ± SD. 
 
 

























Figure 14: Increased proliferation of NF and KF treated with rhActivin-A 
Cultures of NF (a, b) or KF (c, d) were grown until 50% confluence and then serum starved for 
48 hrs. The fibroblasts were then treated with activin-A (100 ng/ml, solid bars) TGF-β1 (1 ng/ml 
dotted bars), TGF-β1 (10 ng/ml, grey bars) then subjected to MTT proliferation assay. Untreated 
samples were used as control (open bars). Values are mean ± SD absorbance at 570 nm as a 
percentage of control. 
 



















Figure 15: Effect of activin-A, follistatin or TGF-β1 on collagen, fibronectin and α-SMA 
expression 
NF or KF were cultured in the absence or presence of different concentrations of activin-A and 
TGF-β1. Cells were harvested, lysed and both cell lysate and conditioned media collected for 
Western blot analysis for collagen, fibronectin or α-SMA. (a) and (b) Lane 1: Untreated NF; Lane 
2: NF + activin-A; Lane 3: NF + TGF-β1; Lane 4: NF4 + follistatin. (c) and (d) Lane 1: Untreated 
KF; Lane 2: KF + activin-A; Lane 3, 4: KF + TGF-β1; Lane 5: KF + follistatin; Lane 6: KF + 
follistatin + activin-A. (e) and (f) Lane 1: Untreated KF; Lane 2: KF + activin-A; Lane 3: KF + 
TGF-β1; Lane 4: KF + follistatin. All of the blots were probed with a β-actin antibody to confirm 
equal loading. For conditioned media 4 ml of conditioned media was concentrated from each 
treatment group to 100 µl which was used for analysis. Histograms represent % OD volume of 
the bands in the corresponding blots. Solid bars represent collagen; striped bars represent α-SMA; 
Open bars represent fibronectin. (g) Lane 1: Untreated KF; Lane 2: KF + activin-A; Lane 3: KF + 
TGF-β1; Lane 4: KF + activin-A (100 ng/ml) + TGF-β1 5 ng/ml. (h) Lane 1: Untreated KF; Lane 
2: KF + activin-A 100 ng/ml; Lane 3: KF + activin-A 50 ng/ml; Lane 4: KF + activin-A (100 































































4.3  DISCUSSION 
 
 
Activin-A, a member of the TGF-β superfamily, has been detected in high levels in 
various inflammatory (Jones et al., 2004) and fibrotic disorders (Hübner et al., 1996; 
Sugiyama et al., 1998; Matsuse et al., 1996, Gaedeke et al., 2005). To confirm its role in 
keloid formation, the present study showed that activin-A was indeed overexpressed in 
keloid tissues. For example, immunolocalization of activin-A was found in the basal 
layers of the epithelium in human skin tissue, but interestingly, keloid tissues showed 
more intense immunolocalization compared with normal tissues. Since epithelial–
mesenchymal interactions have recently been explored as a possible important factor 
contributing to excessive scar formation, in our experimental set-up although there is no 
staining for the fibroblasts, one cannot rule out the paracrine effect of Activin- A 
expressed by KK on KF. 
 
The activin-follistatin system is an important regulatory system controlling cellular 
proliferation and differentiation in many epithelio-mesenchymal organs, including the 
kidney, prostate, mammary gland, lung, pancreas, and salivary gland (Ritvos et al.,1995; 
Hildén et al., 1994; Roberts et al., 1994; Tuuri et al., 1994; Cancilla et al., 2001; Liu et 
al., 1996; Zhao et al., 1996; Miralles et al., 1998; Furukawa et al., 1995; Yamaoka et al., 
1998; Maldonado et al., 2000; Bläuer et al., 1996). When the localization of follistatin in 
keloid and normal tissues was investigated, it was found  to have similar pattern to that of 
activin. The increase in follistatin in the basal layer of keloid tissue is likely due to a 
short-loop negative feedback mechanism operative between activin-A and follistatin 
(Phillips et al., 1998). Taking into consideration the localization and expression of both 
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activin-A and follistatin in the basal layer of the epidermis, where mitotically-active 
keratinocytes are present, one could hypothesize that the activin-follistatin system 
modulates keratinocyte dynamics in tissue repair and keloid pathogenesis (Werner et al., 
2001). 
 
Activin-A, in addition to being a potent activator of fibroblasts, has also been shown to 
have an antiproliferative effect on various types of cells, including epithelial cells, 
lymphocytes, prostate cancer cells, and others (Chen et al., 2002). However, it has been 
observed that many carcinoma cells are somehow able to escape the negative regulatory 
action of activin-A by activating production of follistatin (Dowling et al., 2000; 
Rossmanith et al., 2002). In this study, activin-A was secreted in large amounts by KF 
when compared with NF but KK secreted less. Interestingly, KK secreted more follistatin 
than NK, suggesting that a mechanism similar to that seen in carcinoma cell types might 
be active in KK, where these cells were secreting more follistatin to neutralize the 
activin-A.  
 
Previous work has demonstrated a large amount of ECM deposition below activin-A 
over-expressing keratinocytes (Munz et al., 1999) suggesting that an autocrine, paracrine 
and/or endocrine effect of activin-A might be active in the process of wound healing. In 
the present study, we cocultured activin-A overexpressing keratinocytes (hβAHaCaT 
cells) with NF. An increased proliferation in fibroblasts exposed to hβAHaCaT cells was 
observed as compared to those exposed to both non-cocultured and neo HaCaT cells. 
This could be due to the increased paracrine levels of activin-A in the hβAHaCaT /NF 
coculture system as compared with NK cocultures.This data demonstrated that activin-A 
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secreted from keratinocytes exerted a paracrine effect on the fibroblasts and that an 
excess of activin-A might lead to over-proliferation of these cells, thus leading to fibrosis. 
While analyzing this data one has to take in account that HaCaT cells in which activin-A 
has not been overexpressed, has an endogenous level of this protein and several other 
proliferative factors like IGF-1 (Insulin-like growth factor-1), TGF-β (transforming 
growth factor-beta), interleukins and others. Hence one would expect them to also 
increase the proliferation of the fibroblasts. Other groups have also observed such effects 
when coculturing with neo\HaCaT cells. Skobe’s group (1998) observed that when 
cocultured with HaCaT neo cells, fibroblasts show a 75% increase in cell numbers.  
 
As further substantiation of a pro-proliferative effect of activin-A on human dermal 
fibroblasts, exogenous activin-A increased proliferation of both NF and KF, consistent 
with results from other groups (Ohga et al., 1996; Yamashita et al., 2004). Since TGF-β1 
is known to be an important player in fibrotic disorders and has been demonstrated to be 
highly expressed in KFs (Lee et al., 1999; Younai et al., 1994; Polo et al., 1999), it was 
tested if activin-A and TGF-β1 might act synergistically to stimulate fibrotic processes. 
However, co-treatment of cells with both activin-A and TGF-β1 showed no significant 
synergistic effect.  
 
ECM components are involved in many cellular processes and their patterns of 
expression is different from that usually present in normal skin during different stages of 
wound healing (Costa et al., 1999). Tissue fibrosis is thought to be partly the result of 
excessive induction by TGF-β1, which signals fibroblasts to increase the synthesis of 
ECM, decrease the production of matrix-degrading proteases and increase the production 
 70
of the inhibitors of these proteases (Border et al., 1994). NFs and KFs, when exposed to 
activin-A, increased expression of cytoplasmic collagen (procollagen). Procollagen 
further undergoes post translational modifications (hydroxylation, glycosylation) and 
subsequently forms a triple helix and is secreted out of the cell into the conditioned 
medium. It was observed that there was an increased concentrations of secreted collagen 
in the conditioned media from KFs when treated with activin-A, underscoring the 
importance of activin-A in the regulation of collagen production by dermal fibroblasts in 
keloid pathogenesis.  
 
In addition, there was an increase in the expression of α-SMA, a phenotypic marker for 
myofibroblasts (Yamashita et al., 2004), suggesting activin’s importance in regulating 
expression and contractile activities of α-SMA. Not surprisingly, exogenous follistatin 
had no effect on the expression of ECM components directly, but blocked the activin-
induced increases. Follistatin antagonizes the effect of activin-A by binding to activin 
itself, rendering it inactive (Sugino et al., 1997; Phillips et al., 1998).  
 
In summary, the present study demonstrated that activin-A was upregulated in keloid 
tissues. Keratinocytes overexpressing activin-A stimulated proliferation of dermal 
fibroblasts, suggesting a paracrine role to promote fibroblast proliferation, induce the 
expression of α-SMA, and enhance collagen formation in KFs. However, follistatin, an 
antagonist of activin-A, blocked the expression of ECM components.  Thus, the findings 
strongly suggest that activin-A is a potent inducer of fibroblast activation and involved in 
the pathogenesis of keloids. They also emphasize the importance of follistatin in 
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regulating activin-A bioactivity and suggest a possible therapeutic potential of follistatin 























Figure 16: Activin-A expression increased by epithelial-mesenchymal interactions resulting 
in a fibrotic phenotype.  
KK expressed elevated levels of activin-A which has a paracrine effect on underlying fibroblasts 
thus increasing their proliferative potential and ability to produce ECM components which are 
charecteristics of a fibrotic phenotype. Follistatin can bind to activin-a and render it inactive thus 
having a potential as a possible therapeutic agent. 
 

























































5.1  INTRODUCTION 
 
The TGF-β family of growth factors has been widely studied and is thought to play a 
central role in tissue regeneration by regulating fibroblast proliferation, differentiation 
and matrix production (Derynck et al., 2003; Kim et al., 2000; Niessen et al., 1999; Tuan 
et al., 1998). However various other soluble and insoluble effectors are equally important 
in wound repair and may thus play a part in keloid formation. One such effector group 
comprises cell surface proteoglycans, namely the syndecans, which are a family of 
transmembrane heparan sulphate proteoglycans that are differentially expressed during 
development and wound repair (Carey et al., 1997; Gotte et al., Lories et al., 1992). 
Owing to their unique function of integrating signaling from circulating growth factors 
and ECM proteins with other cellular receptors like the integrins, they have often been 
referred to as “tuners of transmembrane signaling” (Zimmermann et al., 1999). They 
exist as four isoforms: syndecan-1, syndecan-2, syndecan-3 and syndecan-4, each having 
characteristic cell- and tissue-specific distributions throughout development (Bernfield et 
al., 1993; Kim et al., 1994). 
 
Syndecan-2, also called fibroglycan, is especially abundant in mesenchymal cells (Gallo 
et al., 2000) and has been shown to play an important role in diverse biological processes. 
Mouse cells of mesenchymal origin in kidney, lung, and stomach and also in cells that 
form cartilage and bone (David et al., 1993) are known to express high levels of 
syndecan-2. Syndecan-2 modulates cell behavior by affecting cell adhesion and signaling 
(Essner et al., 2006). Chen and his co-workers (2004) demonstrated that syndecan-2  
regulates TGF-β signaling by binding to it through the core protein of its ectodomain. It 
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has been shown to interact with various other cytokines and growth factors, like FGF-2 
and VEGF, and mediate their effects on promoting mesenchymal tissue growth and 
angiogenesis (Burgess et al., 1989; Leung et al., 1989; Besner et al., 1990; Clasper et al., 
1999).  
 
Syndecan-2 has also been implicated in various types of cancers, with increased 
expression demonstrated in human ovarian carcinoma biopsies (Davies et al., 2004) and 
other cancer cell lines (Gulyas et al., 2004). It has also been shown to modulate colon 
cancer cell adhesion, motility and proliferation (Park et al., 2002; Han et al., 2004). 
Owing to these properties, syndecan-2 has recently become a subject of widespread 
research. Its role in carcinogenesis, embryogenesis, wound healing and other clinical and 
physiological conditions is being thoroughly explored. 
 
In addition to heparan sulphate proteoglycans, soluble chondroitin and dermatan sulphate 
proteglycans like decorin have also been shown to play a role in cell-matrix interactions. 
Decorin is an abundant component of bone and skin ECM and associates with type I, II 
and VI collagen fibrils as well as fibronectin in vivo (Laine et al., 2000; Lozzo et al., 
1996; 1998). Decorin is expressed abundantly in NF in which its expression has been 
shown to be enhanced by IL-1 and dexamethasone and inhibited by TGF-β (Laine et al., 
2000; Heino et al., 1988; Kähäri et al., 1995; 1991). Unlike the syndecans, decorin 
inhibits the biological activity of TGF-β by binding with the core protein in various cell 
types (Hilderbrand et al., 1994) and thus has been explored as a potential antifibrotic 
agent. Its antifibrotic effect has been demonstrated in experimental kidney, lung, cerebral 
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and muscular fibrosis (Border et al., 1992; Giri et al., 1997; Logan et al., 1999; 
Fukushima et al., 2001) 
 
In addition to modulating cell-matrix interaction, decorin has also been shown to have an 
antiproliferative effect on various carcinoma cells. The antiproliferative effect of decorin 
was demonstrated to be mediated by either the upregulation of cyclin-dependent kinase 
inhibitors like p21 and p27 or by interacting with various growth factors (De Luca et al., 
1996; Fischer et al., 2001). It was seen that malignant transformation of cells resulted in 
loss of decorin expression. However when decorin expression was restored, it caused 
malignant cell growth arrest, highlighting its protective effect on cellular dynamics 
(Lozzo et al., 1999; Santra et al., 1995).  
 
In the present study, intrinsic syndecan-2, FGF-2 and decorin expressions were studied in 
keloid tissues by performing immunohistochemical analysis and western blot assays. The 
role of serum on the expression profile of syndecan-2 and decorin was further 
investigated by stimulating the NF and KF with 10% fetal calf serum. The role of FGF-2 
in shedding of the syndecan-2 ectodomain and its implications in modulating cell 
behavior was studied by treating KF cultures with recombinant FGF-2 and 
immunoblotting the conditioned media for the expression of syndecan-2. The role of 
epithelial-mesenchymal interactions in modulating syndecan-2, FGF-2 and decorin 
expression dynamics was investigated using an established two-chamber serum-free 
coculture model. In addition, the antifibrotic effect of decorin was studied by 
investigating its effect on the expression of ECM components such as collagen, 
fibronectin and α-SMA. 
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5.2  RESULTS 
 
 
• Keloid scar intrinsically expressed higher levels of syndecan-2 and FGF-2 and 
lower levels of decorin 
 
The expression profiles of syndecan-2, FGF-2 and decorin in keloids and normal skin 
tissues were studied using a western blot assay. Normal skin expressed low levels of 
syndecan-2 (Fig. 17) and FGF-2 (Fig. 22) however decorin was abundantly expressed 
(Fig. 25). In contrast, keloid scar samples had abundant levels of syndecan-2 (Fig. 17), 
FGF-2 (Fig. 22) and low levels of decorin (Fig. 25). Although decorin was 
downregulated in keloid tissues a 32kda band was observed in this sample which was 
completely missing in normal tissue. 
 
• Increased localization of FGF-2 seen in the basal epidermis and dermis of 
keloids compared to normal skin 
 
Paraffin sections of normal skin and keloid scar were subjected to immunohistochemical 
analysis for the expression of FGF-2. Increased levels of FGF-2 were observed in the 
dermis and basal epidermis of keloid scar tissues compared to normal skin (Fig. 21ab). 
FGF-2 also stained strongly in keloid dermis whereas the dermis of normal skin 






• Serum growth factors upregulated syndecan-2 and downregulated decorin 
expression in KF 
 
Stimulation with 10% FCS is interpreted by fibroblasts as a wound healing signal, thus 
NF and KF were treated with 10% FCS to investigate if syndecan-2 and decorin were 
involved in the initial phases of wound healing. Both NFs and KFs showed increased 
levels of syndecan-2 (Fig. 18) on stimulation with serum growth factors, suggesting a 
possible role of syndecan-2 in the initial wound healing mechanism. However, decorin 
expression was downregulated on stimulation with serum (Fig. 26).  
 
• Coculture of KK with KF increased levels of syndecan-2 in the conditioned 
media 
 
To investigate if epithelial-mesenchymal interactions modulate syndecan-2 expression, a 
coculture model was set up wherein NK and KK were cocultured with NF and KF 
respectively. Fibroblasts were subsequently lysed and total cell extracts were subjected to 
western blot. Although no difference was observed in cellular levels of syndecan-2 in 
both NFs AND KFs cocultured with their respective keratinocytes (Fig. 19a), an 
increased level of syndecan-2 was observed in the conditioned media of KK/KF 
cocultures compared to KFs in monoculture (Fig. 19b) suggesting the possible cleavage 







• Cocultured keratinocytes and fibroblasts demonstrated increased expression of 
FGF-2 compared to cells in monoculture 
 
In order to investigate the effect of epithelial-mesenchymal interactions on the dynamics 
of FGF-2 expression, NK and KK were cocultured with NF and KF respectively, with 
cell lysates collected from both groups and blotted for FGF-2 expression. An increase in 
FGF-2 expression was observed in both cocultured keratinocytes (Fig. 23a) and 
fibroblasts (Fig. 24) as compared to those in monoculture, highlighting a possible 
autocrine effect of FGF-2 on keratinocytes as well as a paracrine effect on the underlying 
fibroblasts. In addition, cocultured KKs expressed higher levels of FGF-2 as compared to 
cocultured NKs (Fig. 23b) suggesting a more active mechanism within KKs compared to 
NK. 
 
• Increased levels of decorin found only in the conditioned media from NK/NF 
cocultures as compared to monocultures 
 
Although conditioned media obtained from the coculture of NF with normal NK 
demonstrated higher levels of decorin compared to normal fibroblast monocultures (Fig 
27a), no significant difference in decorin levels was observed in the conditioned media of 
cocultured KFs as compared to KFs in monoculture (Fig 27b) suggesting a loss KK 







• rhFGF-2 increased syndecan-2 cleavage and thus its detectable levels in KF 
conditioned media 
 
The role of FGF-2 in the cleavage of fibroblast syndecan-2 resulting in its increased 
levels in conditioned media was investigated by treating KFs with exogenous FGF-2 and 
analyzing the conditioned media for expression of syndecan-2 by western blot. A 
significant increase in the levels of syndecan-2 was observed compared to untreated KFs 
(Fig. 20). 
 
• Decorin decreased the expression of ECM components in both NF and KF 
 
To investigate the effect of decorin on the expression of ECM components decorin at 
various concentrations (250 ng/ml, 500 ng/ml, 1000 ng/ml and 2000 ng/ml) was added to 
both NF and KF after which cell lysates and conditioned media were analyzed for 
collagen, fibronectin and α-smooth muscle actin expressions. A decrease in the 
expressions of the ECM components was observed both in the cell lysate (Fig. 28a b) and 










Figure 17: Elevated levels of syndecan-2 in tissue extracts obtained from keloid tissue.  
Expression of syndecan-2 in normal and keloid skin tissues were analyzed by western blot assay. 
Study groups comprised of normal skin and keloids. Tissue specimens were sonicated in lysis 
buffer and 100 µg of total protein extracts were subjected to SDS-PAGE and western blotting. 
Blots were hybridized with anti-syndecan-2 polyclonal antibody Lane 1-5: Keloid scar (K50, 
K51, K52, K53, and K54). Lane 6-8: Normal skin (N31, N32, N33). Equal loading was 






Figure 18:  Serum growth factors upregulated syndecan-2 expressions in NF and KF. 
Expression of syndecan-2 by fibroblasts after exposure to 10% FCS was detected by western blot 
assay. Fibroblasts were seeded in 6-well plates at a density of 1 × 104 cells/ml in DMEM/10% 
FCS for 24 hrs and subsequently in serum-free medium for another 48 hr. The fibroblasts were 
subject to either DMEM/10% FCS or serum-free DMEM for 24 hr. Fibroblasts were lysed and 
100µg total protein cell lysates were subjected to SDS-PAGE and western blotting. Blots were 
hybridized with anti-syndecan-2 polyclonal antibody. Lane 1: NF4+DMEM, Lane 2: 
NF4+DMEM/10% FCS, Lane 3: NF14+DMEM, Lane 4: NF14+DMEM/10%FCS, Lane 5: 
KF45+DMEM, Lane 6: KF45+DMEM/10%FCS, Lane 7: KF49+DMEM, Lane 8: 
















Figure 19: Increased ectodomain shedding of syndecan-2 is observed in keloid cocultures as 
compared to monocultures. 
a) Cell lysate obtained from NFs and KFs cocultured with NKs and KKs was assayed by western 
blot for syndecan-2 expression. Cell lysates from NF and KF in monoculture were used as 
controls. No difference in the expression of syndecan-2 was observed in cocultured fibroblast cell 
extracts compared to fibroblasts in monoculture. Lane 1: NF1 non cc, Lane 2: NK1/NF1, Lane 3: 
NF2 non cc, Lane 4: NK3/NF2, Lane 5: KF 45 non cc, Lane 6: KK45/KF45, Lane 7: KF 48 non 
cc, Lane 8: KK48/KF48. b) Conditioned media from KF cocultures were assayed by western blot 
for syndecan-2 expression. Conditioned media from KFs in monoculture were used as controls. 
Equal volumes of conditioned media were subjected to SDS-PAGE. Conditioned media from KF 
cocultures shed more syndecan-2 into the conditioned media as compared to the KF 
monocultures.  Lane 1: KF48 non cc, Lane 2: KK48/KF48, Lane 3: KF45 non cc, Lane 4: 








Figure 20: Exogenous rhFGF-2 stimulated shedding of syndecan-2 from fibroblast cell 
surface into the conditioned media.  
rhFGF-2 (10 ng/ml) was added to the fibroblast cultures and conditioned media assayed for the 
expression of syndecan-2. Conditioned media from untreated KFs were used as controls. Equal 
volumes of conditioned media were subjected to SDS-PAGE. KFs treated with FGF-2 shed more 
syndecan-2 as compared to untreated fibroblasts. Lane 1: KF43 non cc, Lane 2: KF43+FGF-2, 






Figure 21: Increased localization of FGF-2 in the basal layer of epidermis and dermis in 
keloid tissues. 
Paraffin sections of normal (a, c) and keloid (b, d) tissues were prepared and labeled with 
antibodies specific for FGF-2 and observed with microscopy (40x). In each panel, the insert 
shows the same tissue labeled with a non-immune rabbit antibody of the appropriate 
immunoglobulin isotype instead of the specific FGF-2 antibody. Keloid tissues had more intense 
labeling in the basal layer of the epithelium and the dermis compared with normal skin.  The 
localization of FGF-2 (or its lack in the negative control inserts) is shown by an arrow. The 
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Figure 22: Elevated levels of FGF-2 in tissue extracts obtained from keloid tissue. 
Expression of FGF-2 in normal and keloid skin tissues were analyzed by western blot assay. 
Study groups comprised of normal skin and keloids. Tissue specimens were sonicated in lysis 
buffer and 100 µg of total protein extracts were subjected to SDS-PAGE and western blotting. 
Blots were hybridized with anti-FGF-2 polyclonal antibody Lane 1-8: Keloids (K50, K51, K52, 
K53, K54, K55, K56 and K57). Lane 9-13: Normal skin (N31, N32, N33, N34, N35). Equal 
















Figure 23: Cocultured NK and KK expressed increased levels of FGF-2 as compared to 
monocultured keratinocytes. 
Cell lysates from monocultured NK and KK were extracted and analyzed by western blot for the 
expression of FGF-2. Similarly, NKs and KKs which had been cocultured with NFs and KFs 
respectively were lysed and cell extracts were analyzed by western blot for the expression of 
FGF-2. a) Lane 1: NK1, Lane 2: NK1/NF1, Lane 3: KK48, Lane 4: KK48/KF48, b) Lane 1: 
NK1/NF1, Lane 2: NK2/NF2, Lane 3: NK3/NF3, Lane 4: KK48/KF48, Lane 5: KK45/KF45, 










Figure 24: Cocultured NF and KF expressed increased levels of FGF-2 as compared to cells 
in monoculture. 
Cell lysates from monocultured NFs and KFs were extracted and analyzed by western blot for the 
expression of FGF-2. Similarly, NFs and KFs which had been cocultured with NKs and KKs 
respectively were lysed and cell extracts were analyzed by western blot for the expression of 
FGF-2. Cocultured fibroblasts expressed increased levels of FGF-2 compared to moncoultures. 
Equal loading was confirmed by blotting with β-actin for cell extracts Lane 1: NF1, Lane 2: 
NK1/NF1, Lane 3: NF2, Lane 4: NK2/NF2, Lane 5: KF48, Lane 6: KK48/KF48, Lane 7: KF49, 








Figure 25: Downregulation of decorin in tissue extracts obtained from keloid tissue.  
Expression of decorin in normal and keloid skin tissues were analyzed by western blot assay. 
Study groups comprised of normal skin and keloids. Tissue specimens were sonicated in lysis 
buffer and 100µg of total protein extracts were subjected to SDS-PAGE and western blotting. 
Blots were hybridized with anti-decorin monoclonal antibody Lane 1-3: Keloids (K51, K52 and 


























Figure 26: Serum growth factors downregulated decorin expressions in NF and KF. 
Expressions of decorin by fibroblasts after exposure to 10% FCS was detected by western blot 
assay. Fibroblasts were seeded in 6-well plates at a density of 1 × 104 cells/ml in DMEM/10% 
FCS for 24 hrs and subsequently in serum-free medium for another 48 hrs. The fibroblasts were 
subject to either DMEM/10% FCS or serum-free DMEM for 24 hr. Fibroblasts were lysed and 
100 µg total protein cell lysates were subjected to SDS-PAGE and western blotting. Blots were 
hybridized with anti-decorin monoclonal antibody. Lane 1: NF4+DMEM, Lane 2: 
NF4+DMEM/10% FCS, Lane 3: NF14+DMEM, Lane 4: NF14+DMEM/10%FCS, Lane 5: 
KF45+DMEM, Lane 6: KF45+DMEM/10%FCS, Lane 7: KF49+DMEM, Lane 8: 





Figure 27: Increased secretory decorin in cocultured NFs and not KFs. 
NF and KF were cocultured with NK and KK, respectively and conditioned media were collected 
and analyzed for the expressions of decorin. a) Lane 1: NF4+DMEM, Lane 2: NF1+DMEM, 
Lane 3: NF14+DMEM, Lane 4: NF3+DMEM, Lane 5: NK1/NF1, Lane 6: NK2/NF2, Lane 7: 
NK14/NF14, Lane 8: NK5/NF5, b) Lane 1: KF29+DMEM, Lane 2: KF48+DMEM, Lane 3: 
KF49+DMEM, Lane 4: KF25+DMEM, Lane 5: KK48/KF48, Lane 6: KK45/KF45, Lane 7: 









Figure 28: Effect of decorin on collagen, fibronectin and α-SMA expressions. 
NF or keloid fibroblasts KF were cultured in the absence or presence of different concentrations 
decorin. Cells were harvested, lysed and both cell lysates and conditioned media collected for 
western blot analysis for collagen, fibronectin or α-SMA. a) Lane 1: NF1+DMEM, Lane 2: 
NF1+Decorin (250 ng/ml), Lane 3: NF1+Decorin (500 ng/ml), Lane 4: NF1+Decorin (1000 
ng/ml), Lane 5: NF1+Decorin (2000 ng/ml), b) Lane 1: KF48+DMEM, Lane 2: KF48+Decorin 
(250 ng/ml), Lane 3: KF48+Decorin (500 ng/ml), Lane 4: KF48+Decorin (1000 ng/ml), c) Lane 
1: KF48+DMEM, Lane 2: KF48+Decorin (250 ng/ml), Lane 3: KF48+Decorin (500 ng/ml), Lane 



















5.3  DISCUSSION 
 
The healing of any skin injury involves a spontaneous cascade of events comprising 
communication between cells and the release of mediators as growth factors, and 
cytokines, leading to inflammation, cell proliferation, collagen-ECM deposition, scar 
formation, maturation and  ultimately remodeling. Any abnormality or disruption of this 
sequence of events may lead to formation of abnormal scarring which may include keloid 
scars, characterized by excessive collagen-ECM deposition and often, the formation of 
contractures. 
 
Recent advances in this field have seen the role of growth factors being extensively 
investigated. Interestingly, researchers have found most of the growth factors and 
cytokines involved in the wound healing process to be immobilized at the cell surface and 
ECM through binding with proteoglycans (Rouslahti et al., 1991). These proteoglycans in 
turn are known to play important roles in various physiological processes. Besides 
providing mechanical strength by filling in the space between the collagen and elastin 
fibres by absorbing water, they also influence collagen formation, cell proliferation, cell 
migration and cell adhesion during wound healing (Pratibha et al., 2000). 
 
Syndecan-2, a cell surface proteoglycan, plays an important role in the transmodulation 
of the ECM assembly. Since keloid scars are characterized by an aberrant organization of 
the ECM assembly, we investigated if syndecan-2 was being abnormally expressed in 
keloid tissues as compared to normal skin tissues. Western blot analysis of the tissue 
extracts demonstrated that syndecan-2 was indeed upregulated in keloid tissues and that it 
could be one of the factors responsible for the excess deposition of ECM components.  
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In order to understand the underlying biology of syndecan-2 in wound repair and scar 
formations, the expression profiles of syndecan-2 at different stages of the wound healing 
process was investigated using in-vitro models. Upon cutaneous injury, the coagulation 
cascade is activated and an inflammatory response sets in as the first stage of wound 
healing. The active platelet plug sequesters serum in the immediate vicinity providing a 
rich source of cytokines/growth factors with paracrine effects on neighbouring cells. Such 
exposure of fibroblasts to serum is interpreted to be a physiological wounding signal 
(Iyer et al., 1999). It was observed that when NF and KF when exposed to serum growth 
factors expressed increased amounts of syndecan-2 suggesting its possible role in the 
early stages of the healing process and in the modulation of the ensuing events by 
interaction with some of the macrophage-derived growth factors like FGF-2, VEGF, EGF 
(Gotte et al., 2003). The hypothesis that syndecan-2 might be an important player in the 
early phase of the healing process is further strengthened by numerous studies reporting 
syndecan-2 to be induced by proinflamatory cytokines like IL-1α and IL-1β and TGF- β 
which are abundant in the early wound environment (Clasper et al., 1999; Worapamorn 
et al., 2001; Sebestyen et al., 2000).   
 
Strikingly enough, it has been observed that during development, syndecan-2 is localized 
at sites where intensive epithelial-mesenchymal interactions shape and transform the 
epithelia and the mesenchyme into morphologically and functionally differentiated 
tissues suggesting a possible syndecan-2’s role in modulating epithelial-mesenchymal 
interactions (David et al., 1993). Previous findings have shown that epithelial-
mesenchymal interactions play an important role in keloid pathogenesis with KK 
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modulating NF and KF growth and proliferation (Lim et al., 2001), influencing collagen 
expression by both NF and KF, inducing NF to secrete collagen in a keloid-like manner 
(Lim et al., 2002), and utilizing the IGF system of mitogens as inductive ligands for this 
process. Thus to investigate if these interactions would in anyway affect the expressions 
of syndecan-2, NF and KF were cocultured with NK and KK, respectively, and the cell 
lysates and conditioned media blotted. Surprisingly, although no difference in the 
expressions of syndecan-2 from cell lysateswas observed, a definite increase in syndecan-
2 levels was seen in the conditioned media obtained from KFs cocultured with KK. This 
strongly suggests that syndecan-2 was being shed from the KF cell surface into the 
conditioned media under the influence of the overlying keratinocytes. Syndecan-1 and -4 
have been previously shown to be shed from the surface of mouse epithelia and SVEC4-
10 cells in vitro, and factors released during stress, injury and cancer have been 
demonstrated to upregulate this process (Fitzgerald et al., 2000; Elenius et al., 2004; 
Bayer et al., 2001; Seidel et al., 2000; Subramanian et al., 1997). Previous studies by 
Fears’s group (Fears et al., 2006) highlighted the role of syndecan-2 shedding induced by 
various factors, to promote angiogenesis. Of the various factors studied, FGF-2 was 
observed to stimulate syndecan-2 shedding from microvascular endothelial cells. When 
exogenous rhFGF-2 was added to the KF cultures, syndecan-2 shedding was also 
observed, with increased amounts of secreted syndecan-2 found in the conditioned media. 
 
The production and secretion of heparin binding growth factors such as FGF have been 
implicated in various macrophage-mediated processes, including tumor angiogenesis, 
arteriogenesis and capillary sprouting, wound healing, and inflammation (Clasper et al., 
1999). It would appear that the syndecan-FGF system could also be an important player 
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in initiating aberrant wound healing processes leading to fibrosis. As rhFGF-2 increased 
syndecan-2 shedding in KFs, it was investigated if FGF-2 was intrinsically upregulated in 
keloid tissues compared to normal skin and, more importantly, in KK/KF cocultures 
where increased levels of syndecan-2 were observed in conditioned media. Increased 
expressions and localizations of FGF-2 in keloid epidermis and dermis was found as 
compared to normal skin sections. In addition, fibroblasts cocultured with NK and KK 
expressed increased levels of FGF-2 as compared to fibroblasts in single cell culture. 
Interestingly KK/KF cocultures expressed increased levels of FGF-2 as compared 
NK/NF. One arm of keloidogenesis resulting from epithelial-mesenchymal interactions 
would thus appear to involve increased FGF-2 levels which in turn stimulate the shedding 
of syndecan-2 from fibroblasts. This shed syndecan-2 would not only modulate the 
activity of FGF-2 but also other profibrotic growth factors (Han et al., 2004). 
 
FGF-2 has also been demonstrated to decrease decorin mRNA expression in 
osteosarcoma cells. The reduced expression of decorin corresponded with increased 
collagen production by these cell types (Bodo et al., 2002; Wegrowski et al., 2000). 
Since keloids are marked by increased production of type 1 collagen  the expression of 
decorin in keloid tissues was investigated. As expected a decreased expression of decorin 
was observed in keloid tissues as compared to normal skin. Interestingly a 32 kda band 
was observed in keloid tissues probably due to the degradation of decorin to an inactive 
fragment by various MMP’S known to be present in keloids (Fujiwara et al., 2005). 
Previous studies have shown MMP’s to degrade decorin to an inactive fragment which is 
then unable to further bind to TGF-β, releasing it from the ECM with resultant increased 
activity in vivo (Imai et al., 1997). Further studies will be required to assess if this 
 98
mechanism plays a role in keloid pathogenesis. When stimulated with 10% serum, a 
reduction in decorin was observed in both NF and KF. This may be due to negative 
feedback from increased levels of TGF-β and other growth factors in the serum. Previous 
results by Zandvoort’s group (Zandvoort et al., 2006) demonstrated TGF-ß1 stimulation 
to decrease decorin production in isolated pulmonary parenchymal fibroblasts of COPD 
patients.  
 
The effect of epithelial-mesenchymal interactions in modulating the expression of 
decorin in a coculture model was investigated and  it was observed that although NK/NF 
cocultures expressed increased amounts of decorin compared to monocultures, KK/KF 
cocultures did not show any significant difference in decorin levels as compared to 
monocultures. This would suggest that the overlying keratinocytes might have directly or 
indirectly blocked the mechanisms responsible for modulating fibroblast decorin 
expression. FGF-2 demonstrated above to be upregulated in cocultures might well be one 
of the factors responsible, and further studies will be required to confirm this hypothesis. 
 
Finally, it was investigated if exogenous administration of decorin could be used as an 
anti- fibrotic agent. NF and KF were treated with decorin at different concentrations and 
expressions of different ECM components were investigated. It was observed that 
collagen was downregulated on treatment in a dose-dependent manner both in the cell 
lysates and the conditioned media. In addition α-SMA, a phenotypic marker for 
myofibroblasts, and fibronectin were also downregulated on treatment with decorin, 




Overall, it was shown that syndecan-2 and FGF-2 were not only overexpressed in keloid 
tissues but could also interact with each other resulting in the shedding of syndecan-2 
which could in turn activate a whole cascade of events resulting in keloidogenesis (Fig 
29). In addition, decorin appeared to be downregulated in keloid tissues, and this protein 




















Figure 29: Ectodomain shedding of syndecan-2 by FGF-2 stimulated by epithelial-
mesenchymal interactions resulting in a fibrotic phenotype 
One arm of keloidogenesis results from epithelial-mesenchymal interactions which appear to 
involve increased FGF-2 levels which in turn stimulate the shedding of syndecan-2 from 
fibroblasts. This shed syndecan-2 not only modulates the activity of FGF-2 but also other 
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6.1  INTRODUCTION 
 
 
Stem cell factor (SCF), also known as mast cell growth factor, steel factor or KIT ligand 
is a hematopoietic and tissue growth factor that serves as a ligand for the c-KIT oncogene 
(Gabrilove et al., 1994). It is widely expressed throughout the body by stromal cells, 
fibroblasts and endothelial cells (Ashman et al., 1999) and is detectable at a low level in 
the circulation (Broudy et al., 1997; Lyman et al., 1998).  KIT (CD117) on the other 
hand, coded by proto-oncogene c-KIT, is a 145–160 kDa transmembrane tyrosine kinase 
belonging to the type III family of receptor kinases (Yarden et al., 1987). KIT is 
expressed in a variety of normal cells and tissues (Natalie et al., 1992; Lammie et al., 
1994) often with its ligand (Williams et al., 1990). Previous studies have demonstrated 
expression of c-KIT mRNA or protein by mast cells (Mayrhofer et al., 1987; Majumdar 
et al., 1988; Nocka et al., 1989), melanocytes (Nocka et al., 1989), testis (Majumdar et 
al., 1988), and in bone marrow (Wang et al., 1989). In addition c-KIT protein expression 
has been found in non-haemopoietic cell types, including vascular endothelial cells 
(Broudy et al., 1994), astrocytes, renal tubules, breast glandular epithelial cells and sweat 
glands (Natalie et al., 1992; Lammie et al., 1994). Binding of SCF to KIT results in 
dimerisation of the receptors followed by activation of its intrinsic tyrosine kinase 
activity (Blume-Jensen et al., 1991). The interaction between c-KIT and SCF ligand 
plays an important role in hematopoiesis, in mast cell development and function, 
embryogenesis, proliferation and migration of primordial germ cells and melanoblasts 
(Huang et al., 1990; Zsebo et al., 1990).  
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SCF and its receptor c-KIT also play important roles in the process of wound healing. 
SCF-KIT interactions in mast cells trigger degranulation at the site of wounding. The 
released mediators increased fibroblast proliferation and collagen synthesis, contributing 
to abnormal tissue growth leading to fibrosis in various organs (Garbuzenko et al., 2002; 
Fireman et al., 1999; El Kossi et al., 2003). In addition to their role in fibrosis, autocrine 
or juxtacrine cycles involving c-KIT and SCF have been demonstrated to be important in 
some solid tumors, for example, small cell lung cancer (Krystal et al., 1996; Hibi et al., 
1991).  
 
In the present study, owing to its function in wound healing, we hypothesized a role for 
SCF/c-KIT system in keloid scar pathogenesis. Moreover, its upregulation in other 
fibrotic disorders compels its investigation as a possible factor responsible for a keloidic 
phenotype.The results in this study demonstrated that both SCF and c-KIT were 
upregulated in keloid scar tissues in vivo thus corroborating our hypothesis. They were 
also upregulated in cultured fibroblasts on stimulation with serum highlighting their 
importance in the initial phase of wound healing. In addition it was demonstrated that 
epithelial-mesenchymal interactions, mimicked by coculture of keratinocytes and 
fibroblasts in vitro, not only stimulated secretion of soluble form of SCF in keloid 
cocultures but also brought about shedding of the extracellular domain of c-KIT perhaps 
by upregulation of TACE. TACE was also shown to be upregulated in keloid scars in 
vivo and keloid cocultures in vitro. In addition the KIT receptor was activated, as 





6.2  RESULTS 
 
 
• Elevated expression of SCF, c-KIT, phosphorylated c-KIT (Tyr 703, Tyr 721) 
and TACE in keloid scar tissues as compared to normal skin tissues 
 
Stem cell factor (SCF) (Fig. 30) and both mature (145kDa) and soluble (95kDa) forms of 
its receptor c-KIT (Fig. 33a) were found to be overexpressed in keloid scar tissue extracts 
as compared to normal.  In addition phosphorylated forms of c-KIT (tyr 703, tyr 721) 
were also over expressed in keloid scar tissues though the difference was significant only 
in tyr 721 (Fig. 33b). TACE or ADAM17, a known sheddase of many membrane proteins 
was also shown to be expressed at higher levels in keloid scar tissues compared to normal 
skin tissues (Fig. 37). 
 
• Increased localization of c-KIT in the  keloid epidermis compared to normal skin 
 
Immunohistochemical studies were carried out to investigate the expression of c-KIT and 
TACE in normal skin and keloid scar tissues. An increased level of c-KIT expression was 
observed in the basal epidermis (rete-ridge) of keloid scar. The normal skin epidermis 
demonstrated significantly less or negative staining (Fig. 34a b).  
 
• Serum growth factors upregulated SCF levels in KF 
 
Stimulation with 10% FCS is interpreted by fibroblasts as a wound healing signal thus 
NF and KF were treated with 10% FCS to investigate if SCF was involved in the initial 
phases of wound healing. Both NF (Fig 31a) and KF (Fig 31b) demonstrated an increase 
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in levels of SCF on stimulation with serum growth factors suggesting a possible role of 
SCF in the initial wound healing mechanism.  
 
• Coculture of KK with KF increased levels of SCF in the conditioned media 
 
To investigate if epithelial-mesenchymal interactions modulate SCF expression, a 
coculture model was set up wherein KK were cocultured with KF. Fibroblasts were 
subsequently lysed and total cell extracts were subjected to western blot. Although no 
difference was observed in cellular levels of SCF in KF cocultured with KK (Fig. 32a), 
an elevated level of SCF was observed in the conditioned media of KK/KF cocultures 
compared to fibroblasts in monoculture (Fig. 32b). 
 
• Upregulation of c-KIT in KKs as compared to Nks 
 
Normal and keloid cells were cultured for 24 hrs followed by serum starvation for 48 hrs. 
The cells were subsequently treated with growth medium for 24 hrs and subjected to flow 
cytometry.  KKs expressed higher levels of c-KIT as compared to NKs (Fig. 35ab). 
 
 
• Increased levels of c-KIT in cocultured keratinocyte/fibroblast conditioned 
media as compared to monocultures 
 
NKs and KKs were cocultured with NFs and KFs respectively and the cell lysates from 
both the cell types were collected and blotted for c-KIT. A downregulation of c-KIT 
expression was observed in both cocultured keratinocyte (Fig 36a) and fibroblast cell 
lysates (Fig 36b) as compared to monocultures. Phospho c-KIT (tyr 721) was however 
upregulated in keloid cocultured cell lysates as compared to normal coculture lysates 
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indicating activation of c-KIT in coculture conditions (Fig 36e). The conditioned media 
obtained from the cocultured fibroblasts demonstrated elevated levels of c-KIT 
suggesting a possible cleavage of c-KIT into the conditioned media upon coculture (Fig 
36c). In addition higher cleaved c-KIT levels were observed in conditioned media 
obtained from keloid cocultures as compared to normal cocultures suggesting an 
enhanced shedding mechanism prevalent in keloid cocultures (Fig 36d). 
 
• Elevated expression of TACE in cocultured KFs as compared to cocultured NFs 
 
An increased expression of mature TACE was observed in total cell lysates obtained 
from KFs coculutred with KKs as compared to NFs cocultured with NKs suggesting an 














Figure 30: Elevated levels of SCF in tissue extracts obtained from keloid tissues 
Expression of SCF in normal and keloid skin tissues were analyzed by western blot assay. Study 
groups comprised of normal skin and keloids. Tissue specimens were sonicated in lysis buffer 
and 100 µg of total protein extracts were subjected to SDS-PAGE and western blotting. Blots 
were hybridized with anti SCF polyclonal antibody Lane 1-5: Keloid scar (K50, K51, K52, K53). 








































Figure 31:  Serum growth factors upregulated SCF expression in normal and keloid 
fibroblasts. 
Expression of SCF by fibroblast after exposure to 10% FCS was detected by Western blot assay. 
Fibroblasts were seeded in 6-well plates at a density of 1 × 104 cells/ml in DMEM/10% FCS for 
24 hrs and subsequently in serum-free medium for another 48 hrs. The fibroblasts were subject to 
either DMEM/10% FCS or serum-free DMEM for 24 hrs. Fibroblasts were lysed and 100µg total 
protein cell lysates were subjected to SDS-PAGE and western blotting. Blots were hybridized 
with anti-SCF polyclonal antibody. a) Lane 1: NF4+DMEM, Lane 2: NF4+DMEM/10% FCS, 
Lane 3: NF14+DMEM, Lane 4: NF14+DMEM/10%FCS. b) Lane 1: KF45+DMEM, Lane 2: 
KF45+DMEM/10%FCS, Lane 3: KF49+DMEM, Lane 4: KF49+DMEM/10% FCS. Equal 











Figure 32: Increased levels of SCF in conditioned media obtained from keloid cocultures as 
compared to monocultures 
a) Cell lysates obtained from KFs cocultured with KKs was assayed by western blot for SCF 
expression. Cell lysate from keloid fibroblasts in monoculture were used as controls. No 
difference in the expression of SCF was observed in cocultured fibroblast cell extracts compared 
to fibroblasts in monoculture. Lane 1: KF 49 non cc, Lane 2: KK49/KF49, Lane 3: KF 48 non cc, 
Lane 4: KK48/KF48. b) Conditioned media from KF cocultures were assayed by western blot for 
SCF expression. Conditioned media from KF in monoculture were used as controls. Equal 
volumes of conditioned media were subjected to SDS-PAGE. Conditioned media from KF 
cocultures demonstrated higher levels of SCF as compared to the KF monocultures. Lane 1: 










































Figure 33: Elevated levels of c-KIT and Phospho c-KIT (tyr 703, tyr 721) in tissue extracts 
obtained from keloid tissues. 
Expression of c-KIT and Phospho c-KIT at sites tyr 703 and tyr 721 in normal and keloid skin 
tissues were analyzed by western blot assay. Study groups comprised of normal skin and keloid 
scars. Tissue specimens were sonicated in lysis buffer and 100 µg of total protein extracts were 
subjected to SDS-PAGE and western blotting. Blots were hybridized with anti-c-KIT polyclonal, 
Phospho c-KIT tyr 703, Phospho c-KIT tyr 721 monoclonal antibodies. a) Lane 1-5: Normal skin 
(N31, N32, N33, N34, N35) Lane 6-13: Keloids (K50, K51, K52, K53, K54, K55, K56, K57). b) 













Figure 34: Increased localization of c-KIT in the basal layer of epidermis of keloid tissues. 
Paraffin sections of normal (a) and keloid (b) tissues were prepared and labeled with antibodies 
specific for c-KIT and observed with microscopy (40x). In each panel, the insert shows the same 
tissue labeled with a non-immune mouse antibody of the appropriate immunoglobulin isotype 
instead of the specific c-KIT antibody. Keloid tissues had more intense labeling in the basal layer 
of the epithelium compared with normal skin.  The localization of c-KIT (or its lack in the 
negative control inserts) is shown by an arrow. The dermis and epidermis are represented by ‘D’ 




















Figure 35: c-KIT upregulated in KK as compared to NK. 
NK and KK were cultured, trypsinised and then probed with c-KIT monoclonal antibody 
followed by anti FITC conjugated secondary antibody. c-KIT was upregulated in keloid 






































Figure 36: Increased ectodomain shedding of c-KIT in KK/KF cocultures. 
Cell lysates from monocultured NK and KK were extracted and analyzed by western blot for the 
expression of c-KIT. Similarly, NK and KK which had been cocultured with NF and KF 
respectively were lysed and cell extracts were analyzed by western blot for the expression of c-
KIT. Similarly NF and KF in monoculture and coculture were probed with anti-c-KIT and anti 
phospho c-KIT (tyr 721) antibody and subjected to western blot. Conditioned media from normal 
and keloid cocultures were collected and analyzed for the expression of c-KIT. Conditioned 
media from monocultures was used as control. a) Lane 1: NK1 Day 1, Lane 2: NK1/NF1 Day 1, 
Lane 3: NK1 Day 2, Lane 4: NK1/NF1 Day 2, Lane 5: NK1 Day 3, Lane 6: NK1/NF1 Day3, 
Lane 7: NK1 Day 4, Lane 8: NK1/NF1 Day 4, Lane 9: NK1 Day 5, Lane 10: NK1/NF1 Day 5, 
Lane 11: KK 48 Day 1, Lane 12: KK48/KF48 Day 1, Lane 13: KK48 Day 2, Lane 14: 
KK48/KF48 Day 2, Lane 15: KK48 Day 3, Lane 16: KK48/KF48 Day 3, Lane 17: KK48 Day 4, 
Lane 18: KK48/KF48 Day 4, Lane 19: KK48 Day 5, Lane 20: KK48/KF48 Day 5. b) Lane 1: 
NF1, Lane 2: NK1/NF1, Lane 3: NF2, Lane 4: NK2/NF2, Lane 5: KF48, Lane 6: KK48/KF48, 
Lane 7: KF49, Lane 8: KK49/KF49. Equal loading was confirmed by blotting with β-actin for 
cell extracts. c) Lane 1: KF 48, Lane 2: KK48/KF48, Lane 3: KF 49, Lane 4: KK49/KF49. d) 
Lane 1: NK1/NF1, Lane 2: NK2/NF2, Lane 3: NK3/NF3, Lane 4: NK8/NF8, Lane 5: 
KK48/KF48, Lane 6: KK49/KF49, Lane 7: KK45/KF45, Lane 8: KK 44/KF44. e) Lane 1: 
























Figure 37: TACE overexpressed in keloid scar compared to normal skin 
Expressions of TACE in normal and keloid skin tissues were analyzed by western blot assay. 
Study groups comprised of normal skin and keloid scars. Tissue specimens were sonicated in 
lysis buffer and 100 µg of total protein extracts were subjected to SDS-PAGE and western 
blotting. Blots were hybridized with anti-TACE polyclonal antibody. Lane 1-6: Keloids (K50, 














































Figure 38: Upregulation of TACE in KF cocultures as compared to NF cocultures 
Expression of TACE in cocultured NF and KF were analyzed by western blot assay. Lane 1: 
NK1/NF1, Lane 2: NK2/NF2, Lane 3: NK3/NF3, Lane 4: NK8/NF8, Lane 5: KK48/KF48, Lane 







































6.3  DISCUSSION 
 
 
The keloid is a dermal form of FPD characterized by increased proliferation of 
fibroblasts, as well as, increased production of collagen in vitro (Cohen et al., 1990; 
Ladin et al., 1995). Apoptosis-related genes and proteins are believed to be 
downregulated or mutated in keloid tissues and fibroblasts (Sayah et al., 1999; Chodon et 
al., 2000). In this study, the role of SCF and its receptor c-KIT was investigated in keloid 
pathogenesis both in normal skin and keloid tissue sections, as well as in keratinocyte and 
fibroblast cultures. A tyrosine kinsase inhibitor, gleevec was explored as a possible 
therapeutic agent for keloids. 
 
In order to determine the overall expressions of SCF in keloid and normal skin tissues, an 
immunoblot analysis was performed on the tissue extract obtained from keloid and 
normal skin. It was observed that SCF (50kda and 25kda forms) were highly expressed in 
keloids compared to normal tissues, supporting the hypothesis that SCF might play a 
crucial role in keloid pathogenesis. In addition, both mature (145kDa) and soluble 
(95kDa) forms of KIT were found to be upregulated in keloid tissues suggesting a 
possible aberration in receptor-ligand interaction. The tyr703 and tyr721 phosphorylation 
sites have been previously demonstrated to be responsible for the activation of Ras/Erk 
and PI3-Kinase pathways, respectively. A number of studies have implicated the critical 
importance of the Ras/Erk pathway in cell division and survival (Lewis et al., 1998). 
Adaptor proteins like Grb2 can directly associate with phosphorylated tyr703 in KIT 
which may lead to activation of subsequent downstream pathways (Thommes et al., 
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1999). Activation of PI3-Kinase via KIT has been linked to mitogenesis, differentiation, 
survival, adhesion, secretion and actin cytoskeleton reorganization (Yee et al., 1993; 
Timokhina et al., 1998; Serve et al., 1995; Kubota et al., 1998; Vosseller et al., 1997). It 
was found that tyr721 when phosphorylated, interacts directly with PI3-Kinase (Serve et 
al., 1995). In this study, both tyr 703 and tyr 721 phosphorylation sites of c-KIT were 
found to be upregulated in keloid scar tissues compared to normal skin tissues, although 
the difference was significant only in case of tyr 721. 
 
In order to study the localization of the KIT protein in the skin, immunohistochemistry 
was performed to investigate the relative expressions of KIT protein in both keloid and 
normal skin. An increased staining at the basal layer of keloid epidermis was observed 
compared to normal skin. Thus, as the basal layer consists of mitotically active 
keratinocytes, KIT could be playing a major role in modulating the dynamics of these 
active and undifferentiated keratinocytes. These results were confirmed by flow 
cytometry which demonstrated that KKs expressed increased levels of c-KIT as 
compared to NKs. 
 
When fibroblasts are exposed to serum, they interpret it to be a physiological wounding 
signal (Iyer et al., 1999). Hence, exposure to serum reflects how fibroblasts would react 
in vivo in the early phase of wounding.  The increase in SCF observed upon exposure to 
serum in both NFs and KFs suggested that SCF might have a role in early wound healing 
process. This is consistent with previous studies, which found that SCF peaked on the 
first day of wounding. The increase in SCF production increased the activation of mast 
cells and triggered their degranulation, leading to the release of factors such as IL-1α and 
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TNF-α that lead to inflammation, which is an early response in wound healing (Huttunen 
et al., 2002). 
 
Previous findings have shown that epithelial-mesenchymal interactions play an important 
role in keloid pathogenesis with KK modulating the growth and proliferation of NF and 
KF (Lim et al., 2001), influencing collagen expression by both NF and KF, inducing NF 
to secrete collagen in a keloid-like manner (Lim et al., 2002), and utilizing the IGF 
system of mitogens as inductive ligands for this process. Thus to investigate if these 
interactions in anyway affected expression of SCF and its receptor c-KIT, NF and KF 
were cocultured with NK and KK and blotted. No significant differences in SCF 
expression between the fibroblast cell lysates derived from coculture and monoculture 
was observed. However an increase in SCF levels was detected in the conditioned media 
derived from the cocultures. ADAM19 and ADAM33 in COS and HEK293 cells 
(Chesneau et al., 2003; Zou et al., 2004), MMP- 9 in hematopoetic stem cells (Heissig et 
al., 2002), IL1-β produced by keratinocytes (Da silva et al., 2002) have all been shown to 
promote cleavage and secretion of SCF. The soluble SCF can then act as a proliferative 
agent (Ren et al., 2003). The mechanism by which epithelial-mesenchymal interactions 
brought about an increase in secreted levels of SCF is not know and further studies are 
needed to be unravel to delineate the mechanism. The role of the interactions between the 
mesenchyme and the epithelium on the expression of c-KIT was further investigated. 
Although the phosphorylated levels of c-KIT (tyr 721) were elevated in keloid cocultures 
as compared to normal cocultures, both the keratinocytes and fibroblasts which had been 
cocultured expressed decreased amounts of c-KIT compared to that from monoculture. 
However the conditioned media obtained from these cocultures demonstrated elevated 
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levels of the receptor suggesting a shedding of c-KIT. Keloid cocultures demonstrated 
increased levels of soluble c-KIT as compared to normal cocultures. To investigate the 
mechanism by which c-KIT was cleaved, a sheddase TACE, which was previously 
demonstrated to be critical for shedding of c-KIT (Cruz et al., 2004) was explored. Not 
only an increase of mature active TACE in keloid tissue extracts compared to normal 
tissue extracts was observed but also found it to be upregulated in cocultured KF cell 
lysates  compared to cocultured NF confirming the prevalence of a TACE mediated 
shedding mechanism. Although the presence of an ectodomain shedding exists in keloid 
cocultures, the role of soluble c-KIT in keloid pathogenesis is still unclear.  It has been 
previously reported that binding of SCF results in rapid kinase activity-dependent 
receptor endocytosis, ubiquitination and degradation (Yee et al., 1993; 1994; Miyazawa 
et al., 1994). Activation of the receptor also results in cleavage and release of the soluble 
extracellular domain (Yee et al., 1993; 1994; Miyazawa et al., 1994; Brizzi et al., 1994) 
which then competes for the ligand with the membrane bound form (Broudy et al., 1997). 
These mechanisms are activated as a negative feedback response to regulate ligand 
receptor induced signal transduction. A similar mechanism may exist in keloid cocultures 
where increased activation of c-KIT, as seen by increased level of phospho c-KIT, results 
in ectodomain shedding by proteolytic cleavage. There have been numerous studies 
demonstrating presence of soluble c-KIT, as a negative feedback response, in serum in 
various disorders (Tajima et al., 1998; Kawakita et al., 1995). Alternative to the negative 
feedback hypothesis, the soluble c-KIT bound to the free SCF ligands in the ECM, may 
also help to increase the retention of the ligand in the extracellular environment, resulting 
in a prolongation of the half-life due to the increased size and stability of the complex 
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(Broudy et al., 1997; Peters et al., 1996). By prolonging the overall half-life of the SCF 
ligand, the soluble KIT receptors may then serve to stabilize free SCF levels between 
peaks and valleys of SCF secretion, leading to the sustained activation of the SCF-KIT 
pathways (Heaney et al., 1995). Thus to confirm the exact role of ectodomain shedding 
observed, more mechanistic studies are warranted to ascertain the behavior and effect of 
the soluble KIT receptor-SCF complexes in vivo.  
  
In summary, it has been shown for the first time that SCF and its receptor c-KIT were 
both upregulated and activated in keloid tissues. In addition, epithelial–mesenchymal 
interactions seemed to modulate both the dynamics of SCF and c-KIT resulting in their 
shedding into the conditioned media, a process mediated probably by TACE (Fig 39a, 
39b). Given these results the SCF/c-KIT system might be a target for therapeutic 













Figure 39: c-KIT system in keloid pathogenesis 
a) SCF loop: Under the influence of the overlying keratinocytes, fibroblasts produce soluble SCF 
which not only has an autocrine effect but also a paracrine effect on the keratinocytes thus 
forming a short positive loop system between the two.. b) c-KIT shedding: Epithelial-
meenchymal interactions result in mature KIT (145kDa) to be cleaved by proteolytic enzymes 
(TACE) thus releasing soluble KIT (95kDa) into the ECM. The soluble c-KIT then binds to SCF. 
The soluble KIT can be either a result of a negative feedback mechanism to regulate the 
overactivated scf/c-KIT system in keloidic cells or can be a mechanism in itself to activate the 
KIT system by increasing the half life and stability of SCF by binding to it  and resulting in its 
sustained effect. 
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7 INVESTIGATION OF GLEEVEC AS A THERAPEUTIC 



























7.1  INTRODUCTION 
 
 
In the past, a wide variety of treatments has been used for keloids, including intralesional 
corticosteroids, surgery, cryosurgery, silicone gel sheeting, radiotherapy, pressure 
therapy, and laser therapy like flashlamp pulsed-dye laser treatment. Newer therapies like 
interferon α2b, bleomycin injections and intralesional 5-fluorouracil (5FU) have also 
been explored. Unfortunately, various side-effects like severe pain, ulceration, necrosis 
and hyperpigmentation limit the utility of all these treatments (Nanda et al., 2004, Mustoe 
et al., 2002). Neither of the mentioned therapies proved to be effective for patients, 
underscoring the need to discover alternatives.  
 
Having identified SCF and its tyrosine kinase receptor c-KIT to be upregulated and 
activated in keloid pathogenesis, it was explored if a tyrosine kinase inhibitor could be 
used as a possible therapeutic agent for keloid scars. In recent years, biopharmaceutical 
research has actively targeted protein kinases for the treatment of several neoplastic 
diseases. Two FDA approved examples are Gleevec™ (Imitanib Mesynate – Novartis 
AG) for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors 
and Iressa™ (Gefitinib - AstraZeneca) for the treatment of metastatic non-small cell lung 
cancer by inhibiting intracellular tyrosine kinase phosphrylation.  
 
Gleevec essentially inhibits four kinases: Bcr-abl, c-abl, c-KIT and PDGF (Capdeville et 
al., 2002). As imatinib is an inhibitor of the receptor tyrosine kinases for PDGF and SCF, 
it is able to block PDGF and SCF-mediated cellular events (Lefevre et al., 2004). 
Gleevec in particular has been previously demonstrated to be effective for the treatment 
of chronic myeloid leukemia (CML) by blocking cell proliferation and inducing 
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apoptosis in Bcr-abl- expressing CML. It has been effective against gastrointestinal 
stroma tumor (GIST) owing to its inhibitory action on KIT (Sattler et al., 2004). It has 
also been demonstrated to have antifibrotic effects in organ fibrosis like lung fibrosis 
(Aono et al., 2005) and renal fibrosis (Wang et al., 2005).  
 
In the present study, the effects of various concentrations of gleevec on the proliferation 
of KK and KF was explored by MTT assay. Studies were performed to further investigate 
if gleevec was able to inhibit the c-KIT pathway by blotting with antibodies against 
phospho c-KIT and the ensuing molecules in the PI-3 kinase pathway. The expression of 
the ECM components like collagen, fibronectin and α-smooth muscle actin and the 
expressions of profibrotic and pro-angiogenic growth factors like VEGF, TGF-β, HDGF, 
FGF-2, SCF on treatment with gleevec were also monitored. To investigate if gleevec 
could reduce scar contracture, an in-vitro model which consisted of a FPCL was used and 
its contraction on treatment with gleevec studied. Finally the effect of gleevec on the 
bioenergetics of the cell was investigated by studying the intracellular ATP and the rate 









7.2  RESULTS 
 
 
• No significant difference in the proliferative potential of KK and KF on 
treatment with gleevec 
 
Gleevec was added in varying concentrations (0.5, 1, 2.5, 5, 10, and 20 µg/ml) in 
presence of 5% v/v serum to KK and KF and MTT assay was performed. No significant 
difference was observed in the proliferative potential of both keratinocytes and fibroblast 
on treatment with gleevec (Fig. 40). 
 
• Gleevec inhibited the SCF/c-KIT pathway by dowregulating the 
phosphorylation of c-KIT at tyr 721, Akt and mTOR 
 
KFs were treated with 5 µg/ml of gleevec in DMEM containing 5% v/v serum for 15 
min, 1 hr and 24 hrs.Total extracts from cells were probed with antibodies against 
phosphorylated forms of c-KIT (Tyr 721), Akt and mTOR. A decrease in the expression 
of phospho c-KIT, phospho Akt and phospho mTOR was observed within 15 minutes of 
treatment with gleevec (Fig. 41).  
 
• Gleevec downregulated the expressions of ECM and profibrotic factors in KFs 
in a dose-dependent manner 
 
Gleevec in presence of 5% v/v serum was added in varying concentrations (2.5, 5, and 
10µg/ml) to KFs and the total cell extracts subjected to western blot. Significant decrease 
in levels of collagen, fibronectin and α-SMA were observed on treatment with gleevec in 
a dose-dependent manner (Fig. 42a). A significant decrease in expression levels of 
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profibrotic factors like VEGF, HDGF, TGF-β1, SCF, and FGF-2 were also observed 
(Fig. 42b). 
 
• Gleevec decreased the contraction of collagen lattice populated by KF in a dose -
dependent manner. 
 
FPCL were prepared as previously described and treated with various conentrations of 
gleevec in a medium containing 5% v/v serum for 48 hrs. The medium was subsequently 
removed and the lattices stained by rhodamine solution to give it a pink colour. The 
lattices were then photographed and the area calculated as previously mentioned for side-
by-side analysis. It was observed that collagen lattices populated with Keloid-derived 
fibroblasts demonstrated significantly lesser contraction when treated with gleevec as 
compared to collagen lattices treated with medium containing 5% v/v serum which was 
used a control (Fig 43). Lattices in serum-free media were used a negative controls. 
 
• Gleevec reduced the rate of ATP synthesis and intracellular ATP levels in KFs. 
 
KFs were treated with gleevec (5 µg/ml) for 24 hrs and subjected to luciferin-luciferase 
assay. The rate of ATP synthesis in KF was decreased on treatment with gleevec at a 
concentration of 5 µg/ml. In addition the intracellular ATP levels in KFs were also 






Figure 40:  No significant difference in the proliferative potential of KK and KF. 
KKs and KFs were treated with different concentrations of gleevec in 5% serum (0.5, 1, 5, 10, 20 
µg/ml). Cells were subjected to MTT assay after 24hrs of treatment. Untreated fibroblasts in 5% 
serum were used as control. Fibroblasts in DMEM only were used as a negative control. No 












Figure 41: Gleevec downregulated expression of Phospho Akt, Phospho mTOR, Phospho c-
KIT (tyr 721). 
KFs were treated with gleevec (5 µg/ml) and the cell lysates were collected after 15 min, 1 hr, and 
24 hrs of treatment. The lysates were blotted with antibodies against Phospho Akt, Phospho 
mTOR, Phospho c-KIT (tyr 721). Gleevec downregulated the expression of phosphor Akt, 
Phospho mTOR and Phospho c-KIT (tyr 721) after 15 min. KFs treated with 5% serum were used 
as control. Lane 1: KF48 +DMEM with 5% serum after 15 min, Lane 2: KF48 + gleevec (5 
µg/ml) in 5% serum after 15 min, Lane 3: KF48 +DMEM with 5% serum after 1 hr, Lane 4: 
KF48 + gleevec (5 µg/ml) in 5% serum after 1 hr, Lane 5: KF48 +DMEM with 5% serum after 24 
hrs, Lane 6: KF48 + gleevec (5 µg/ml) in 5% serum after 24 hrs.  Equal loading was confirmed 











Figure 42: Gleevec downregulated expression of collagen, fibronectin, α-SMA, VEGF, 
HDGF, TGF-β1, SCF, FGF-2. 
Keloid fibroblasts were treated with different concentrations of gleevec in 5% serum (2.5µg/ml, 
5µg/ml). After treatment for 24hrs the cells were lysed and blotted with antibodies against 
extracellular matrix components like a) collagen, fibronectin, α-SMA and b) profibrotic factors 
like TGF-β1, SCF, VEGF, HDGF, FGF-2. Untreated fibroblasts in 5% serum were used as 
controls. Lane 1: KF48 +DMEM with 5% serum, Lane 2: KF48+ 2.5µg/ml gleevec in 5% serum, 
Lane 3: KF48+ 5µg/ml gleevec in 5% serum. Equal loading was confirmed by blotting with β-









Figure 43: Gleevec significantly reduced the contraction of collagen gel lattice incorporated 
with keloid fibroblasts. 
The fibroblast populated collagen lattices were treated with various concentrations of gleevec 
(0.5µg/ml, 2.5µg/ml, 5µg/ml, 10µg/ml) for 48hr. The lattices were then collected and stained with 
Rhodamin B and photographed. a) KF 48+DMEM, b) KF48 +DMEM with 5% serum, c) KF48+ 
0.5µg/ml gleevec in 5% serum, d) KF48+ 2.5µg/ml gleevec in 5% serum, e) KF48+ 5µg/ml 


















Figure 44: Gleevec significantly reduced the intracellular ATP and the rate of ATP 
synthesis in KF. 
KFs were treated with gleevec (5 µg/ml) for 24 hrs and analysed for the levels of intracellular 
ATP. The rate of ATP synthesis was also calculated in the treated samples with untreated samples 











7.3  DISCUSSION 
 
 
In this study, no significant difference in the proliferative potential of KK and KF on 
treatment with various concentrations of gleevec was observed. This was in accordance 
with previous studies by Distler and his co-workers (2006) in which they reported that 
gleevec showed no effect on the proliferative potential of dermal fibroblasts. However 
gleevec was able to reduce the expression of ECM components, like collagen, 
fibronectin, α-SMA significantly in KF in a dose-dependent manner highlighting its 
importance as a potential antifibrotic agent. Gleevec also downregulated TGF-β and 
VEGF which have been previously shown to be upregulated in KF (Kim et al., 2000; Xia 
et al., 2004; Ong et al., 2007). It was dowregulated expression of HDGF which was 
previously reported to be involved in organ development and modeling (Mori et al., 
2004) and recently demonstrated to be upregulated in keloid tissues (unpublished). FGF-2 
and SCF, growth factors implicated in various fibrotic disorders (Yu et al., 2003; 
Garbuzenko et al., 2002), were also downregulated upon treatment with gleevec in a 
concentration-dependent manner. the effects of gleevec on FPCL, an established 3-d 
wound contraction and scar contracture model (Bell et al., 1979) was further tested. 
Gleevec was significantly reduced the contraction of the lattices thus highlighting its role 
in modulating scar contracture. 
 
Having demonstrated an antifibrotic effect of gleevec, it was explored if gleevec owed its 
inhibitory activity to c-KIT receptor inactivation. Activation of PI-3 kinase via KIT has 
been linked to mitogenesis, differentiation, survival, adhesion, secretion and actin 
cytoskeleton reorganization (Yee et al., 1993; Timokhina et al., 1998; Serve et al., 1995; 
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Kubota et al., 1998; Vosseller et al., 1997). It was found that tyr721 when 
phosphorylated, interacts directly with PI-3 kinase (Serve et al., 1995). Within 15 min of 
treatment with gleevec, the expression of phospho c-KIT (tyr 721) in KF was reduced. In 
addition, downstream signaling molecules like phospho Akt and phospho mTOR were 
also downregulated in these KF suggesting an inhibition of the P13 kinase pathway in 
these fibroblasts on treatment with gleevec.  
 
Ueda’s team (1999) previously demonstrated a high level of ATP for a longer time in KF. 
Thus we investigated if gleevec could reduce the intracellular ATP levels as well as the 
rate of ATP production in KF. It was observed that gleevec could significantly decrease 
both the rate of ATP production, as well as total intracellular ATP levels in KFs. 
However the mechanism by which it has such an effect needs to be explored.  
 
To summarize, this study demonstrated that a selective tyrosine kinase inhibitor, gleevec, 
was able to downregulate the expression of ECM components, as well as profibrotic 
factors in KFs via inhibition of the c-KIT mediated PI3 kinase signaling pathway. It was 
also able to make the KFs less bioenergetic by reducing the ATP levels. Thus given its 










The achievement of this project is the identification and elucidation of novel molecular 
pathways in the pathogenesis of keloid scars.  Using a large database of clinical tissue 
samples from keloid and normal patients and various in vitro models of wound repair, it 
was demonstrated for the first time that activin-A, stem cell factor (SCF) and its tyrosine 
kinase receptor c-KIT, fibroblast growth factor-2 (FGF-2) and proteoglycans like 
syndecan-2 and decorin play important roles in keloid pathogenesis and could be possible 
targets for therapeutic intervention. Development of specific antibodies that antagonize 
these growth factors or block its receptor could result in reduced collagen accumulation, 
predicated on the results of this study. Similarly, based on these results, there is a scope 
for development of peptide antagonists or receptor decoy molecules based on molecular 
modeling of the receptor–ligand binding characteristics. Another approach would be to 
screen for small molecules, potentially identifying compounds that antagonize the 
receptors and its downstream signaling.  
 
In addition to identifying these new targets, this study also underscores the importance of 
epithelial-mesenchymal interactions in keloid pathogenesis. The interaction between the 
dermis and the overlying epidermis was demonstrated to be critical in scar contracture 
and in modulating the biology of activin-A, SCF/c-KIT, FGF-2, syndecan-2 and decorin 
in keloid scars. This observation may have immense clinical relevance. Currently 
available therapy involves the intralesional corticosteroid injection which is very painful 
for the patients. Having demonstrated the importance of the epithelium, topical 
application of chemical agents and antagonists of profibrotic growth factors could be 
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used as novel delivery systems thus making the therapy more patient compliant and 
friendly. 
 
Another interesting data which sprouted from this study was the shedding of the c-KIT 
receptor in keloidic conditions which had been previously shown to occur in malignant 
disorders. Keloids, although ‘benign’, have always been acknowledged to possess growth 
autonomy to a certain degree resembling malignant tissues, resulting in the invasion and 
involvement of adjacent skin in the course of its growth, and thus the clinical description 
of the keloid as a scar that exceeds the boundaries for the original wound or incision. The 
finding of c-KIT receptor shedding might well reflect growth autonomy in keloid 
fibroblasts resembling transformed cells.  
 
This study went on to explore new pharmacological interventions. This resulted in the 
identification of growth factors, like follistatin and decorin, and chemical agents like 
gleevec, as potential therapeutic agents for keloid scars. Follistatin is a natural antagonist 
of activin-A and having identified activin-A as a player in keloids, it could be used as a 
potential therapy. In this study follistatin was shown to downregulate the expression of 
ECM components like collagen, fibronectin and α-SMA. Another growth factor which 
was shown to be effective in downregulating ECM significantly was decorin. The 
observation that decorin is downregulated in keloid scars and exuberantly expressed in 
normal skin underscores its importance in normal wound repair. Finally having identified 
a tyrosine kinase receptor namely c-KIT to be important in keloid pathogenesis, a well 
known FDA-approved tyrosine kinase inhibitor, gleevec, was explored. Using in vitro 
models for anti-scar research experimentation, it was found that gleevec could reduce the 
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expression of ECM components, as well as key profibrotic and pro-angiogenic growth 
factors like VEGF, TGF-β, and HDGF. In addition it was also able to downregulate SCF 
and FGF-2, which were also identified in this study, as key regulators of keloidogenesis. 
Gleevec reduced contractile s of KF and also rendered the fibroblast less bioenergetic. At 
the molecular levels, gleevec was shown to effectively block the PI-3 kinase mediated 
SCF/c-KIT pathway. Figure 45 summarizes the growth factors involved in keloid 

















Figure 45: Summary of growth factors involved in keloid pathogenesis and possible 
therapeutic targets.          
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